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Résumé  
Objectifs: Examiner les tendances temporelles, les déterminants en lien avec le design des 
études et la qualité des taux de réponse rapportés dans des études cas-témoins sur le cancer 
publiées lors des 30 dernières années. 
Méthodes: Une revue des études cas-témoins sur le cancer a été menée. Les critères d'inclusion 
étaient la publication (i) dans l’un de 15 grands périodiques ciblés et (ii) lors de quatre périodes 
de publication (1984-1986, 1995, 2005 et 2013) couvrant trois décennies. 370 études ont été 
sélectionnées et examinées. La méthodologie en lien avec le recrutement des sujets et la collecte 
de données, les caractéristiques de la population, les taux de participation et les raisons de la non-
participation ont été extraites de ces études. Des statistiques descriptives ont été utilisées pour 
résumer la qualité des taux de réponse rapportés (en fonction de la quantité d’information 
disponible), les tendances temporelles et les déterminants des taux de réponse; des modèles de 
régression linéaire ont été utilisés pour analyser les tendances temporelles et les déterminants des 
taux de participation. 
Résultats: Dans l'ensemble, les qualités des taux de réponse rapportés et des raisons de non-
participation étaient très faible, particulièrement chez les témoins. La participation a diminué au 
cours des 30 dernières années, et cette baisse est plus marquée dans les études menées après 
2000. Lorsque l'on compare les taux de réponse dans les études récentes a ceux des études 
menées au cours de 1971 à 1980, il y a une plus grande baisse chez les témoins sélectionnés en 
population générale ( -17,04%, IC 95%: -23,17%, -10,91%) que chez les cas (-5,99%, IC 95%: -
11,50%, -0,48%). Les déterminants statistiquement significatifs du taux de réponse chez les cas 
étaient: le type de cancer examiné, la localisation géographique de la population de l'étude, et le 
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mode de collecte des données. Le seul déterminant statistiquement significatif du taux de réponse 
chez les témoins hospitaliers était leur localisation géographique. Le seul déterminant 
statistiquement significatif du taux de participation chez les témoins sélectionnés en population 
générale était le type de répondant (sujet uniquement ou accompagné d’une tierce personne).  
Conclusion: Le taux de participation dans les études cas-témoins sur le cancer semble avoir 
diminué au cours des 30 dernières années et cette baisse serait plus marquée dans les études 
récentes. Afin d'évaluer le niveau réel de non-participation et ses déterminants, ainsi que l'impact 
de la non-participation sur  la validité des études, il est nécessaire que les études publiées 
utilisent une approche normalisée pour calculer leurs taux de participation et qu’elles rapportent 
ceux-ci de façon transparente.  
Mots clés: épidémiologie, méthodes épidémiologiques; études cas-témoins; cancer, taux de 
participation; taux de réponse, collecte de données 
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Abstract  
Objectives: To examine the time trends, study design determinants, and quality of reporting of 
response rates in published case-control studies of cancer over the past 30 years.  
Methods: A review was conducted of case-control studies of cancer. Inclusion criteria required 
publications in 15 major journals, during four publication periods spanning three decades (1984-
86, 1995, 2005 and 2013). 370 studies were selected and reviewed. Information on study base 
ascertainment, data collection methods, population characteristics, response rates, and reasons 
for non-participation was extracted. Quality of response rate reporting was assessed based on the 
amount of information reported. Descriptive statistics were used to summarize the quality of the 
reporting, time trends and the determinants of response rates; linear regression models were used 
to analyse time trends and determinants of response rates. 
Results: Overall, the quality of reporting of response rates and reasons for non-participation was 
very poor, especially for control series. Participation has declined over the past 30 years, and this 
decline was steeper in studies conducted after 2000. When comparing the response rates in 
recent studies to that in studies conducted during 1971-1980, there was a greater decline of this 
rate in population controls (-17.04%, 95% CI:     -23.17%, -10.91%) than in cases (-5.99%, 95% 
CI: -11.50%, -0.48%). Statistically significant determinants of response rates among cases were: 
cancer type examined, location of the study population, and mode of data collection. The only 
statistically significant determinant of response rates among medical source controls was 
location of the study population.  The only statistically significant determinant of response rates 
among population controls was type of respondent (self only or self and proxy) accepted by 
studies. 
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Conclusion: Response rates in case-control studies of cancer seem to have declined and this 
decline has accelerated in recent studies. In order to appreciate the true level of non-participation 
and its determinants, as well as the impact of non-participation on validity of studies, there is a 
need for more transparent reporting and standardized calculation of response rates in published 
studies.  
Key words: epidemiology, epidemiologic methods; case-control studies; cancer, response rate; 
participation rate, data collection  
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1  Introduction 
 
1.1 Case-control study design and its application for cancer research 
 
A dictionary of epidemiology (1) defines the case-control study as a study design which 
classifies people based on a disease outcome where the cases have the disease of interest, and in 
which a suitable control group consists of people without the disease. The relationship of an 
exposure to the disease of interest is examined by comparing cases and controls with regard to 
frequency of exposure or, levels of the exposure, in each group (1). 
This design is one of the most utilized types of study design in analytical epidemiological 
research, and has contributed greatly in improving our understanding of the etiology of many 
diseases with great public health importance (2-4). The first recognized modern case-control 
study was conducted in 1926 by a British physician named Lane-Claypon to study the role of 
reproductive experience in the etiology of breast cancer (5). It wasn’t until the 1950s that this 
design, referred to at the time as a ―retrospective study‖, became more widely used (2, 6, 7). The 
increasing interest in this method was partly attributable to its successful implementation in four 
influential case-control studies which established the causal relationship between cigarette 
smoking and lung cancer (8-11). Indeed, this design is particularly useful to study cancer 
etiology because cancer is a rare disease with a long induction period. Adopting this design 
permits researchers to enroll a sufficient number of cancer patients within a relatively short 
period of time, thus economizing time and maximizing efficiency (3, 4, 12). 
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1.2 Control selection in case-control studies 
 
In case-control studies, the primary goal for control selection is to ensure a representative 
covariate distribution in selected controls to that of the source population of cases (3) (13).  
Wacholder et al (13) proposed three comparability principles to minimize bias in control 
selection. The first is the principle of study base, in which cases and controls should come from 
the same source population; the second is the principle of deconfounding, in which the 
confounding factors should not be allowed to distort the estimation of risk under study, and the 
third is the principle of comparable accuracy, in which the degree of accuracy in exposure 
measurement should be equivalent for cases and controls. Common types of controls employed 
by epidemiologists include population-based and medical-source-based controls (3). Some 
common fallacies in control selection could include restrictions to only controls at risk of 
exposure of interest, or to only controls that are healthy (3).  
1.3 Non-response bias in case-control study design 
 
The primary concern of an epidemiologic study is to ensure the validity of the estimate of 
association between an exposure and a disease (3). The validity of this estimate could be 
compromised due to a selection bias, which occurs when there is a distortion in the sampling 
frame or in the procedures used to select subjects or in factors that influence study participation 
(3). Non-response bias is a type of selection bias in survey-based case-control studies where the 
probability of subject participation differs by exposure level and by disease outcome or by 
factors associated to them (14). Response rates have often been used as an indicator to estimate a 
study’s potential for non-response bias; the lower the rates, the higher the chance that 
participants do not accurately represent the target population, hence increasing the chance of 
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producing biased risk estimates of association (14, 15). It is believed that subject participation in 
epidemiologic studies has declined over the past decades (14) and that this decline is steeper in 
controls than in cases (16), which increases a case-control study’s potential for non-response 
bias. 
1.4 Definition of “response rate”    
 
It would make little sense to compare response rates between different case-control 
studies if each study defined, calculated and reported response rates differently (14, 15, 17, 18). 
In other words, a response rate cannot be interpreted if no explanation is provided to explain its 
meaning. The lack of explanation would not only increase the reader’s chance of misinterpreting 
the validity of the reported results, but would also make it impossible to properly compare  
response rates provided by different studies (19, 20). Indeed, this is one of the major problems 
with the study of response rates. The term ―response rate‖ (theoretically, it should be better 
addressed as ―response proportion‖) has been defined in different ways, and is often used 
interchangeably with other terms such as ―participation rate‖ and ―cooperation rate‖ (14). 
Appendix 1 provides several examples of the definitions of response rate, cooperation rate and 
participation rate. 
In practice, the ambiguity of the definition of response rates often lies in the choice of 
denominator for its calculation (14, 18). In addition, the definition and calculation of response 
rate differ depending on the study design selected.  Although there is no official rule defining 
how a response rate must be calculated (19), there have been suggestions made to standardize its 
definition and calculation.  
In household telephone surveys where subject eligibility is unknown prior to being 
contacted, response rate is often calculated as the number of households who participated 
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divided by the total number of households selected (20). The American Association for Public 
Opinion Research (AAPOR) (21) and the Public Opinion Research in the Government of Canada 
(22, 23) provide a similar definition for response rate. They define it as the number of 
participants divided by the sum of the numbers of participants, nonparticipants (including 
refusals and noncontacts), and persons of presumed but unconfirmed eligibility (21-23) .  
In epidemiologic studies, the response rate is defined as the number of people 
interviewed divided by those who were selected and eligible for the study (15, 20). For the 
purpose of this thesis, we are mainly interested in studying response rates in epidemiologic 
studies, specifically in case-control studies. Similar to social survey research, the main source of 
confusion regarding the definition and calculation of response rates in case-control studies, lies 
within the denominator, and the concept of subject eligibility (19). For example, subjects who 
are unable to be contacted, in poor health, or are forbidden to be contacted by their doctors, are 
often deemed as ineligible by researchers and are excluded from the denominator, resulting in a 
―response rate‖ that is artificially inflated (19, 20).  
 
1.5 Impact of response rates on validity of results   
 
If a study has low response rates and if non-respondents are different from respondents 
with regard to the exposure variable and disease status under study, the estimates of relative risk 
may be biased (3, 24). Harris et al. (25) used data from a case-control study plus simulations to 
assess the degree of error of observed odds ratio (OR) over the true OR when different levels of 
non-response bias were introduced in a sample. The level of this bias was manipulated through 
the inclusion of different proportions of exposed and non-exposed cases in the sample. They 
concluded that even a low level of non-response bias could yield a dramatic impact on the 
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observed OR, either inflating or attenuating the true OR. There are advanced statistical methods 
available to input values to replace the missing data due to nonresponse; however, such methods 
cannot be implemented when characteristics of the non-respondents are not missing at random, 
which is often the case (24). 
Although it is clear in theory that studies with lower response rates have greater 
likelihood of nonresponse bias, the extent of such bias depends on the pattern of non-response in 
the four cells of the 2x2 table of cases/controls by exposed/unexposed. In practice, sometimes 
low overall response rates produce little bias and sometimes they produce considerable bias. (14-
16, 18, 26). However, the more we know about the reasons for nonresponse, the more we can 
speculate about a study’s likelihood of bias. Thus, it is crucial that authors provide a well-
documented report of response rates (14, 18, 27). This reporting should include the efforts made 
to examine the presence of nonresponse bias, and if possible, the methods used to try to reduce it, 
so that readers can judge the validity of each study. Unfortunately, the reporting of nonresponse 
bias in epidemiologic studies was rarely examined. In a study that examined this issue using 81 
published articles, 57% of the articles did not mention the possible effects of nonresponse bias 
and only 17% briefly mentioned it in the discussion (28). 
1.6 Determinants of response rates   
 
Many epidemiologists believe that it is becoming more and more challenging to obtain 
high response rates in epidemiologic studies (3). This could be the result of a general decrease in 
civic participation in scientific studies over the past years; moreover, recent epidemiologic 
studies have been facing increasing obstacles imposed by ethics review authorities in accessing 
subject(14). The main factors that have been investigated previously regarding their effects on 
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response rates are individual level sociodemographic characteristics such as sex, education, 
health or employment status (14, 16, 29), with varying results. There has been little investigation 
of study design factors such as subject recruitment and interview methods  (3, 14). 
1.7 Response rates in case-control studies of cancer  
 
Because of to the lack of consistency and transparency in the calculation and reporting of 
response rates, it is difficult to properly evaluate its determinants and time trends (14, 19). 
Although there is evidence indicating a decline in subject response rates in epidemiologic case-
control studies (14-16, 30), they all suffer from very small sample sizes and collected few data 
on the determinants of the response rate. Moreover, the current state of subject participation in 
case-control studies of cancer is unknown, as findings on this topic have not been updated for the 
past decade. 
Therefore, it is important to establish: 1) how response rates are calculated and reported, 
2) what are the typical levels of response rate seen in recent case-control studies, 3) whether 
there is a trend in response rates of case-control studies of cancer and, 4) what are the 
determinants of response rates.  This thesis attempts to elucidate these issues.  
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2 Literature review 
 
Search strategy  
 
We identified and included in this review of literature pertinent publications in English 
through the PubMed and Google Scholar search engines, using a combination of keywords (case-
control studies, epidemiologic studies, response rate, participation, cancer, questionnaire, 
research methods, epidemiologic methods, non-response).  
 
2.1 Reporting of response rates  
 
The quality of reporting for subject participation in published case-control studies was 
rarely evaluated. No data exists on the quality of response rate reporting in studies published in 
the last 10 years. However, one study published in 1995 speculated that the quality of reporting 
has deteriorated over time (20). One review (16) that examined this issue in 2003highlighted the 
general poor quality of reporting of response rates in epidemiologic studies , and concluded that 
56% of case-control studies failed to report any information on response rates. One commentary 
published in 2012 (15) suggested that in our current era where study recruitment and data 
collection methods have evolved in complexity, and where subject recruitment and data 
collection have been facing increasing external restraints, no simple definition of response rates 
can be applied to all studies. Instead, studies should describe in detail the ascertainment method 
for the eligible study population and the methods used to contact and collect information from 
them. Response rates should be documented at every stage of the study and reasons for non-
participation should be documented as well. If possible, characteristics of participants and 
nonparticipants should also be provided (15). 
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Although there was a lack of reporting of response rates in published studies, efforts have 
been made to improve the reporting quality of subject participation in epidemiologic studies. In 
2007, a group of epidemiologists and survey methodologists developed a statement named the 
Strengthening the Reporting of Observation Studies in Epidemiology (STROBE) to promote 
detailed reporting of study methods in observational epidemiologic studies (31). This statement 
consists of a checklist providing guidance to authors about proper reporting for observational 
studies, and includes suggested methods to report response rates (31). However, the evidence of 
its effect on the reporting of this rate is still lacking. 
 
2.2 Time trend of response rates  
 
It is widely believed that subject response rates in epidemiologic studies have declined 
over the past decades (14); many epidemiologists believe that the rate of this decline has 
accelerated, and this decline is steeper for controls than cases (16). However, those concerns 
were often expressed in the form of commentaries or editorials, actual time trend analyses of 
response rates in epidemiologic studies are lacking. The few published studies (16, 20, 32-34) 
that examined this trend in case-control studies analyzed data in studies conducted from the 
1970s to the early 2000s. No data exists on the time trend of response rates in studies conducted 
over the last decade. 
 A majority (20, 33, 34) of the previous publications (16, 20, 32-34) that examined subject 
response rates in case-control studies only studied subject participation in population controls. 
Slattery et al (20) compared the response rates of population controls recruited using the random-
digit dialing method in two American cancer studies conducted in the mid-1980s to two similar 
studies conducted in the late 1970s or early 1980s, and reported that population controls’ 
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response rates had declined by 16-28% during this period. Another publication (33) examined 
the amount of researchers’ efforts needed to maintain high response rates in population controls 
in the United States, and concluded that the amount of effort needed to maintain  high control 
participation nearly doubled from 1991 to 2003. Three reviews (16, 32, 34) have examined the 
time trends of response rates in surveyed case-control studies conducted between 1970s to the 
early 2000s. Two reviews examined the time trends of response rates in North American or 
German populations in case-control studies published from the 1980s to the 1990s, and 
concluded that subject response rates did not change significantly until the late 1990s. One 
review (16) examined time trends of response rates in case-control studies conducted from 1970 
to 2003, and reported significant declines of response rates in both cases (-1.18% per year) and 
controls (-1.49% per year); in addition, they reported steeper but non-significant declines of 
response rates observed in studies conducted from 1990 to 2003. 
  
2.3 Determinants of response rates  
 
Given the importance of response rates in epidemiologic studies, it is essential to study its 
determinants. During the past three decades, there has been an observed downward trend in 
participation in scientific studies due to broader social reasons, which epidemiologists have no 
control over (14). Factors such as the emergence of telemarketing and political polls, and the 
population’s general decrease in volunteerism in social participation all play an important role in 
shaping response rates (14, 15). Subjects’ sociodemographic characteristics, such as sex, SES, 
education, health status, employment status, marital status, being exposed to the exposure of 
interest, and having the disease being examined, have also been shown to influence subject 
participation (14, 18, 29, 35-37). However, researchers have no control over the 
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sociodemographic characteristics of their sampled population and there was little evidence of 
effective strategies that can be applied to all studies to increase participation via targeting 
specific sociodemographic characteristics (14). Yet, certain study design factors have been 
shown to be associated with the probability of success in enrolling subjects in epidemiologic 
studies. Evidence from reviews that examined studies published prior to the mid-2000s 
concluded that studies contacting subjects in person had a tendency to yield higher response rates 
than studies using telephone or other less personal forms of contact (14, 20, 30, 38, 39). Studies 
using incentives, with shorter interview/questionnaire length, or involving non-invasive 
procedures have also been associated with higher response rates (14, 18). However, as 
technology and society evolve over time, it is possible that factors that influence response rates 
in one era play a different role in another era (15, 40, 41). In addition, as new methods for 
recruitment and data collection have been introduced, such as web-based questionnaire and 
biologic sample collection , there is an emerging need to study the impact on response rates of 
the use of such methods (30). Meanwhile, the enhanced scrutiny introduced by institutional 
review boards through privacy laws has also imposed major challenges in subject recruitment for 
epidemiologic studies, thus lowering subject response rates and preventing the collection of 
information from nonparticipants for comparison purposes (14, 25, 42-46).   
 
2.4 Overview of evidence  
 
Current assessments of time trends, determinants, and quality of reporting of response 
rates in case-control studies are lacking. Previous reviews reported inconsistency in the trends, 
calculation, and reporting of response rates in epidemiologic case-control studies published from 
the 1970s to the early 2000s. Although response rates alone do not determine the presence of 
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selection bias, the lack of information provided by authors on non-respondents hinders the ability 
of the readers to judge the validity of the study and to compare it to others. Response rates and 
nonresponse bias have been heavily investigated in social survey research, but analogous effort is 
lacking in epidemiologic studies. The few reviews that have examined these issues in case-
control design all suffered from small sample sizes, and thus were unable to explore in detail the 
reasons for non-participation and the determinants of subject participation for each subject series. 
Moreover, their findings on the time trends of response rates were based on the authors’ reported 
value of this rate. Given the inconsistency in the methods used to calculate response rates in 
published studies, and the rapid evolution of survey instruments used in epidemiologic studies in 
recent years, coupled with the changes in privacy laws imposed on researchers regarding 
epidemiologic research, it is timely to conduct an up-to-date review of these issues to inform the 
current and past levels of subject participation in case-control studies of cancer. Namely, there is 
a need to conduct new reviews with bigger sample sizes, adopting more rigorous definition of 
response rate, and providing more detailed information on potential study design determinants, to 
provide an updated assessment of subject response rates in case-control studies of cancer.  
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3 Objectives of this research   
 
In this methodological investigation, we will examine the trends and characteristics of 
subject response rates in the context of questionnaire-based case-control studies of cancer. Our 
objectives are 1) to describe the quality of reporting of response rates in case-control studies of 
cancer and the evolution of reporting quality over the past 30 years, 2) to assess the current level 
and time trend of response rates in case-control studies of cancer, and to examine study design 
determinants that are associated with this rate. 
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4 Methods 
 
4.1 Search strategy and Sample selection  
 
 This is a review of questionnaire-based case-control studies of cancer that were published 
over the past 30 years. Over this entire period there would undoubtedly have been many 
thousands of articles describing case-control studies of cancer. It would have been impossible to 
review them all individually in the context of a master’s thesis. Furthermore, in an initial 
exploration of the usefulness of PubMed searches, we found that there was no reliable way to 
find all case-control studies as this was not a universally-used keyword, especially in earlier 
years, and even less successful was the attempt to find studies using keywords concerning 
response rates. The methodology we envisaged would require an in-depth review of each 
identified study. Given the enormous number of such studies and the practical limitation of not 
being able to review them all, and the impracticality of using PubMed searches for this purpose, 
we had to develop a strategy to restrict numbers but yet maintain relevance. Namely we decided 
to search all issues one-by-one of selected journals in selected years and concerning certain 
broad topics. This required a selection of a limited number of journals, as trying to review every 
journal in which a case-control study might conceivably have been reported was utterly 
impractical. Even when we had identified a limited number of journals, the number of articles to 
go through was so large that we had to select certain years of publication to keep the project 
feasible.  
The selection of journals was based on the opinions and the records of Dr Jack 
Siemiatycki, and on a limited PubMed search. Dr Siemiatycki has been one of the leading cancer 
epidemiologists over this period of time. In addition to being a leading researcher, he was an 
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associate editor of journals and a frequent reviewer of manuscripts for journals and of articles for 
various expert panels, often for studies involving cancer epidemiology. He has amassed a 
personal database of cancer epidemiology articles that numbers in the thousands. He first 
considered and provided his opinions on which were the main journals for cancer case-control 
studies over this period. This was then compared with the list of citations in his extensive 
database of articles, and then it was compared with the PubMed search we carried out, referred to 
above. While neither the PubMed search nor the extensive list of articles in Dr Siemiatycki’s 
database can be considered complete, we used them to compile a list of journals in which such 
articles appeared. Putting these different elements together, we settled on 15 journals as the ones 
that were the main vehicles for publication of cancer case-control studies. Some of these journals 
did not exist for the entire period. There certainly may have been relevant studies in some other 
journals but these would have been few and we believed that the large investment of time of 
going through the journal issues one-by-one would not be justified by the number of pertinent 
articles we might find. Further, we restricted attention to articles published in certain mid-point 
calendar years in each decade. Further, because the issues in cancer studies may be distinct from 
those in some other disease studies, and so as to avoid mixing in too many issues, and because 
the numbers of studies that we could review was already very large with cancer studies, we 
restricted this investigation to cancer case-control studies. Further, because the issues of 
conducting such studies may be qualitatively different between advanced industrial societies and 
developing societies, both in terms of the systems available to ascertain and approach subjects, 
and the cultural framework in which people react to requests to participate in research, we tried 
to restrict attention to studies conducted in the main developed countries of North America and 
Europe and Australia or New Zealand. Further because the issues around soliciting participation 
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of children are different from those of soliciting participation among adults, and because there 
was already a very large number of studies to review among adults, we restricted attention to 
studies among adults. 
No documentary record was maintained of this process. There was no attempt to identify 
and count all the journals that might conceivably report case-control studies. There was no 
attempt to identify and count all the articles that were published in those journals over the entire 
time period or during the selected years of publication. There was no attempt to count all the 
case-control studies that were conducted outside the selected countries.  There was no attempt to 
identify and count all the case-control studies among children in those or other journals. There 
was no attempt to identify and count all the studies of diseases other than cancer in those or in 
other journals. 
To summarize and to expand on the selection criteria, to provide a portrait of response 
rate reporting and response rate levels for the entire period of time without reviewing an 
inordinate number of publications, we instituted the following inclusion criteria:  1) Studies had 
to be published in one of the 15 selected journals during the following four sub-periods: 1984-
1986, 1995, 2005, and 2013. We chose a 3-year period to represent the mid-1980s because of the 
relatively small number of studies per year before 1990. These journals and time periods defined 
the set of journal issues that we reviewed one-by-one to seek articles that satisfied the following 
criteria.  2) Studies had to focus on cancer etiology in adults.  3) Studies had to be conducted in 
North America, Europe, Australia, or New Zealand. 4) Studies had to have adopted the classic 
case-control design; nested case-control or case-cohort studies were excluded. 5) Studies had to 
include at least 50 cases or 50 controls, so as to minimize statistical instability of parameters of 
interest. 6) Studies had to entail data collection from subjects or their proxy respondents using 
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questionnaire instruments; pure record linkage studies were excluded.  7) We only included the 
latest publication if multiple reports were produced using the same case and control series.  
If the selected publication did not mention subject participation, we sought relevant information 
from other reports by the study team. Two reviewers (MX and SC) independently screened every 
article in every issue of each journal in the targeted years, using the above criteria for inclusion. 
There was virtually perfect concordance between the reviewers. This was a qualitative informal 
comparison. In the rare case of uncertainty, the two reviewers consulted each other or other 
members of the team to achieve consensus decision on eligibility. No record was kept of 
instances of uncertainty. Figure 1 shows the flowchart of study sample selection. 
4.2 Data Collection 
  
For each eligible article, MX extracted the following detailed information: journal name, 
publication year, data collection period, location of the studied population, cancer type, type of 
control series (population, medical-source, and friends and/or family control series), mode of 
data collection (in-person, mail, telephone, or multiple methods), type of respondent accepted 
(self only, proxy only, or self and proxy), and terminologies used by authors to describe level of 
subject participation (―response rate‖, ―participation rate‖, ―cooperation rate‖, or multiple 
terminologies used). For each case and control series, we extracted information on eligible 
subjects, participants, subject refusal, subject deceased or too ill during the survey period if no 
proxy respondents were allowed or found, subject unreachable, and lastly subject not interviewed 
due to medical source obstacles (such as physicians refusing access to their subjects or medical 
staff being unable to carry out a gatekeeper function). When present, we also recorded each 
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study’s eligibility criterion in regard to the presence of medical source obstacles for certain cases 
or controls. 
It is not meaningful to try to distinguish between cases coming from population-based 
and from hospital-based studies because, unlike the controls in such studies, there is no necessary 
difference in the way such subjects are approached or their likely ―state-of-mind‖. Further, the 
distinction between population-based and hospital-based studies is in fact often ambiguous. For 
instance, a study which ascertains cases from all hospitals and diagnostic centers in an area may 
be considered hospital-based by some, but in fact provides a complete ―population-based‖ listing 
of cases. If the controls in such a study are selected from the general population via RDD or 
electoral lists or another such source, we would call them population-based controls. If the 
controls are selected from among patients with other diseases in the same hospitals in which the 
cases are ascertained, we would call them hospital-based controls. There is no rational basis for 
labelling cases as hospital-based or population-based on the basis of how the controls are 
selected. Nor is there any reason for thinking that cases would react differently if they are part of 
a study in which only the cases from one hospital are recruited versus a study in which cases 
from all hospitals in an area are recruited. 
4.3 Response Rate definition 
 
 The response rate is defined as the number of participants divided by the number of 
eligible subjects. While the number of participants is easily defined, the number of eligible 
subjects, the denominator, can have different interpretations, depending on the investigators’ 
treatment of different subsets of non-participants. The reasons for non-participation are typically: 
subject refusal, subjects deceased or too ill, subject unreachable for some reason, subject unable 
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to speak the local language, subject not contacted due to medical source obstacles (e.g. this might 
refer to a physician refusing access to a patient, or a member of medical staff failing to contact 
the patient). In a case-control study we endeavour to obtain data from a representative sample of 
cases in the study base and a representative sample of non-cases in the study base, conditional on 
certain covariates (13). Exclusion of any of the subsets of non-participants, whether among cases 
or controls, could lead to biased estimates of risk, and they will if the prevalence of exposure to 
the risk factor of interest differs by subset. Thus, in the absence of knowledge of exposure 
prevalence among all those subsets, one should endeavour to include them all, and failure to do 
so represents a threat to validity of the study’s findings. Thus, the denominator for computing 
response rate should include all of the subsets of non-respondents listed above. The one 
exception to this rule is that if the study base can be legitimately redefined to exclude subjects in 
any of the subsets, and if that subset can be completely excluded from the study, then that subset 
does not need to be included in the denominator (or numerator) of response rate. Among the 
subsets listed above, the only one that could legitimately satisfy such criteria is the language 
problem subset. Consequently in assessing quality of reporting, we adopt the following definition 
of a response rate:                      
 
4.4 Response Rate Reporting Quality Measurement 
 
We examined the time trends of response rate reporting for the case, medical source 
control and population control series separately in our surveyed studies. In order for a reader to 
fully understand what the reported response rate in a paper truly means, it is necessary to know 
how the authors dealt with each of the components of ―eligible subjects‖ in the above formula. 
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We created a scoring system to evaluate the quality of reporting of subject response rate; we 
assigned to each of these five components a reporting quality rating of either “low”, “medium”, 
or “high”. This rating was defined as: ―low‖ = no information was provided in the study on this 
component and it cannot be calculated from information provided; ―medium‖ = some 
information was provided, either explicitly or implicitly, that permitted an estimate of this 
component, but there was some ambiguity in the information that detracted from certainty (e.g., a 
response rate was provided but the number of eligible subjects was unknown); ―high‖ = there 
was clear explicit information that allowed for an estimation of this component with high 
confidence (e.g., the number of eligible subjects and the response rate or the total number of 
participants were both explicitly provided). 
In addition to assigning a quality rating for each component of response rate calculation 
of a study, we created an overall quality score to represent each study’s overall response rate 
reporting quality. This score represents a study’s overall presentation of number of true eligible 
subjects, number of true participants and true response rate. It is an ordinal score ranging from 
―0‖ to ―3‖; Score ―0‖ indicates that no information was provided on subject participation; ―1‖ 
indicates that there were information provided on eligible subjects and total participants, but no 
information was provided on reasons for non-participation; ―2‖ indicates that there was 
information provided on eligible subjects, total participants,  and some information on reasons 
for non-participation; and ―3‖ indicates that there was comprehensive information provided on 
subject participation, including information on eligible subjects, total participants, and all 4 
possible reasons for non-participation: subject refusal, subject deceased or too ill, subject 
unreachable, and medical source obstacle (when appropriate). 
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4.5 Response Rate Calculation 
 
To the extent that the published papers provided the required data, we calculated response 
rates for each case and control series based on our formula presented above, and thus, the 
recorded response rates are not necessarily the same as the ones published by the investigators. 
When applicable, we also recorded whether studies treated non-respondents due to ―medical 
source obstacles‖ as eligible. When studies did not provide sufficient information that allowed 
for a calculation of their response rates using the above formula, we recorded the rates reported 
by the authors. 
4.6 Statistical analyses  
 
We examined the time trends of response rates, separately for cases and each type of 
controls, using univariate linear regression models. Response rate (the outcome variable) was 
measured as the proportion of persons who participated, and time (the predictor variable) was 
measured as the mid-point year of data collection of each study, and was categorized into 4 time 
periods (1971-1980, 1981-1990, 1991-2000, 2001-2010); the period 1971-1980 was defined as 
the reference group. Time trends of each nonresponse rate (subject refusal, deceased or too ill, 
unreachable, and medical source obstacle(s)) were also examined using similar methodology. 
We also conducted sensitivity analyses using only self-respondent response rates, since the 
quality of interview conducted with proxies might be less reliable compared to that of self-
respondents, which may result in information bias. To explore the yearly change in response 
rates within each time period and subject series, we carried out regression analyses using a linear 
spline model. Potential study design determinants of response rate for each subject series were 
examined using the following multivariate linear regression model: response rate (%) = b0 + b1x 
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cancer type (only applicable to cases) + b2 x study population (dichotomous) + b3 x mode of 
data collection (dichotomous) + b4 x type of respondent accepted + b5 x biologic sample 
collection + b6 x data collection period. All these potential determinants were considered to be 
the main independent variables and were entered together into the multivariate model; they were 
adjusted for each other and for time. The constant b0 represents the response rate for studies with 
the reference category for each variable. The other beta coefficients represent the percentage 
change in response rate for studies in the selected category when compared to the reference 
category, adjusted for the remaining variables.  Potential study design determinants of response 
rate included study population (North America / Northern Europe, or others), cancer type (only 
applicable for cases), mode of data collection (in-person, or others), type of respondent accepted 
(self only, proxy only, or self and proxy), and  biologic sample collection (invasive, non-
invasive, or none). We also describe the response rates as a function of the quality of reporting of 
response rates. The reporting quality index for each study was derived by a method described by 
Xu et al (2016) (47); it ranges from 0 (no information) to 3 (full information).Tests of statistical 
significance were two sided, with an alpha level of 0.05. Statistical analyses were conducted 
using SPSS (IBM SPSS Statistics, Version 20.0. Armonk, NY: IBM Corp). 
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5 Manuscripts 
 
The methodology and results of this investigation will be presented in two 
separate manuscripts. The first manuscript aims to describe the quality of reporting of 
response rates in case-control studies of cancer and the evolution of this reporting over 
time; the second manuscript aims to assess the current level and time trend of response 
rates in case-control studies of cancer, and to examine study design determinants that are 
associated with this rate. 
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Abstract 
Background: The validity of results from case-control studies depends in part on 
response rates; however, inconsistent quality of reporting between studies hampers our 
ability to appreciate the true magnitude of response rates and the trend over time.  
Objective: To describe the quality of reporting of response rates in published case-
control studies of cancer over the past 30 years.  
Methods: A review of case-control studies of cancer published in 15 major 
epidemiology, public health and general medicine journals was conducted. Four 
publication periods (1984-86, 1995, 2005 and 2013) were reviewed. Information on study 
base ascertainment, data collection methods, population characteristics, response rates, 
and reasons for non-participation was extracted. Quality of response rate reporting was 
assessed based on the amount of information reported.  
Results: 370 studies conducted during 1961-2010 were reviewed, yielding a total of 370 
case series and 422 control series. Overall, the quality of reporting of response rates and 
reasons for non-participation was poor. There was a tendency for better quality of 
reporting in case series, followed by population control series, and lastly by medical 
source control series. A peak in response rate reporting quality was observed in studies 
published in 1995. Reporting quality has deteriorated since then.  
Conclusion: The reporting of relevant information on response rates in case-control 
studies of cancer was rather poor, which compromises our ability to assess validity of 
studies’ findings. It would be helpful for a consensus to emerge regarding the reporting 
and calculation of response rate, based on the principle of maximal disclosure. 
 
Key words: case-control studies; cancer; epidemiologic methods; response rate; 
participation  rate 
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Background 
  In case-control studies, the response rate is often used as an indicator of 
the representativeness of a sample to the target population, and thus as an indicator of 
potential selection bias due to non-participation (14-17, 19, 30). It is widely believed that 
subject response rates in case-control studies of cancer have declined over the last 
decades (14, 48, 49), that the rate of this decline has increased in recent years, and that 
the decline was steeper in controls than in cases (16, 33). It is further believed that the 
declining response rate is a particular problem in case-control studies of cancer (32). 
 The term ―response rate‖ is defined in different ways, and is often used 
interchangeably with other terms such as ―participation rate‖ and ―cooperation rate‖ (14). 
As defined in authoritative works of survey research (50) , participation rate is a general 
term and both ―response rate‖ and ―cooperation rate‖ are particular types of participation 
rate. Namely, ―response rate‖ is defined as the number of complete interviews divided by 
the number of all potential eligible interviews, whereas ―cooperation rate‖ is defined as 
the proportion of subjects interviewed divided by the number of eligible subjects ever 
contacted. The nuance between the two terms is that ―response rate‖ includes the subjects 
that were unable to be contacted into the denominator but ―cooperation rate‖ does not; 
hence by its nature, the ―response rate‖ is a more conservative measure of the 
―participation rate‖ (14).  Similarly, in epidemiologic usage,  ―response rate‖ is defined as 
the number of people interviewed divided by those who were eligible for the study (15, 
20). Unfortunately, to date there is no universal standard for defining subject eligibility 
(the denominator) (19). For example, subjects who are unable to be contacted, are in poor 
health, are forbidden to be contacted by their physicians, or who do not speak the local 
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language, and hence are generally not interviewed are treated inconsistently by authors in 
terms of whether they should or should not be included in the denominator of response 
rate calculation (19, 20). Moreover, authors would often not report such information, 
leaving it impossible for readers to have a full disclosure of their eligibility criteria  (50, 
51). 
 Given that response rate is often used to indicate the potential for selection bias 
due to subject nonparticipation (14, 17, 26), it would make little sense to compare this 
rate between studies if it is defined, calculated, or reported differently in each study (14, 
15, 17, 18). The lack of information provided would not only increase the opportunity for 
readers to misinterpret the validity of the reported risk estimates, but would also make it 
almost impossible to compare the potential of selection bias between studies (19, 20, 49, 
52). Therefore, it is important that investigators report meaningful information about their 
computation of response rates. Unfortunately, the quality of reporting for this parameter 
is often questionable (14-16, 31, 53); moreover, it has been speculated that the quality of 
reporting has deteriorated over time (20). The aim of our study was to describe the 
quality of reporting of response rates in case-control studies of cancer and the evolution 
of reporting quality over the past 30 years. 
Methods 
Sample selection of published studies 
 This is a review of questionnaire-based case-control studies of cancer that were 
published over the past 30 years. In a preliminary exercise we established that PubMed 
and other automatic search methods were not reliable in identifying all case-control 
studies, and even less, in identifying those that reported response rates. We realized that 
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we would have to review all articles in certain journals one-by-one. Given the enormous 
number of studies in all journals and the practical limitation of being able to review them 
all, we instituted a strategy to restrict numbers but yet maintain relevance. Based on our 
large bank of reprints of cancer case-control studies published since the 1980s, we 
identified fifteen international journals of epidemiology, public health and general 
medicine that seemed to be the main vehicles for publication of epidemiological studies 
of cancer during this period. Some of the selected journals did not exist for the entire 
period. We further restricted attention to articles published in certain calendar years in 
each decade, namely 1984-1986, 1995, 2005, and 2013. For those selected journals and 
those years, we ―manually‖ examined each issue and each article, and selected those that 
satisfied the following additional inclusion criteria: 1) We restricted attention to case-
control studies focusing on etiology of cancer in adults. 2) Fifteen major journals of 
epidemiology, public health and general medicine that we believed to be the main 
vehicles for publication of epidemiological studies of cancer during the past 30 years, 
were selected. Some of these journals did not exist for the entire period. 3) Four sub-
periods of publication were selected: 1984-1986, 1995, 2005, and 2013. We chose a 3-
year period to represent the mid-1980s because the number of studies per year was much 
lower before 1990.  4) The studies were conducted in North America, Europe, Australia, 
or New Zealand. 5) The studies involved the classic case-control design; nested case-
control or case-cohort studies were excluded. 6) There were at least 50 cases or 50 
controls in the studies, so as to minimize statistical instability of parameters of interest. 7) 
The study entailed data collection from subjects or their proxy respondents using 
questionnaire instruments; pure record linkage studies were excluded.  8) If multiple 
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publications were produced based on the same case and control series, we only included 
the latest publication. If a selected study referred to a previous publication for more 
detailed information on study methods, we extracted information on subject participation 
from its previous publication. Two reviewers (MX and SC) independently screened every 
article in every issue of each journal in the targeted years, using the above criteria for 
inclusion. There was a virtually perfect concordance between the reviewers. This was a 
qualitative informal comparison. In the rare case of uncertainty, the two reviewers 
consulted each other or selected members of the team to achieve consensus decision on 
eligibility. Figure 1 shows the flowchart of study selection. 
Data Collection  
For each eligible article, we collected information on contextual characteristics of 
publications, such as journal name and publication year. We also collected information 
on study design and study population characteristics, including cancer type examined 
(categorized based on cancer cell morphology and patient survival rate), location of the 
studied population, study’s data collection period, and types of control series, the main 
types being  population controls and medical source controls, and friends and/or family 
controls. Population control series could be selected from sources such as population 
registers, electoral lists, random digit dialing, driver’s license, governmental medical 
insurance lists and neighbours of cases. The medical source control series were selected 
from sources such as hospitals, Health Maintenance Organization (HMO) or General 
Practitioner (GP) lists, and cancer or death registers. Data collection methods of the 
surveyed studies were recorded into the following variables: mode of data collection (in-
person, mail, telephone, or multiple methods), type of respondent accepted (self-only, 
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proxy-only, or self and proxy), use of financial incentives (Y/N), persons responsible for 
soliciting subject participation (research team or medical personnel).We also recorded the 
terminology used by authors to describe ―response rate‖ (―response rate‖, ―participation 
rate‖, ―cooperation rate‖, or multiple terminologies used).  
For each study, we extracted separately for case and each control series the 
information on eligible subjects, participants, subject refusal, subject deceased or too ill 
during the survey period and no proxy respondents were allowed or found, subject 
unreachable, and lastly subject not interviewed due to medical source obstacle (such as 
physicians refusing access to their subjects or medical staffs being unable to carry out a 
gatekeeper function). When present, we also recorded each study’s eligibility criterion in 
regard to the presence of medical source obstacles for certain cases or controls. 
Response Rate definition 
 The response rate was defined as the number of participants divided by the 
number of eligible subjects. While the number of participants is easily defined, the 
number of eligible subjects, the denominator, can have different interpretations, 
depending on the investigators’ treatment of different subsets of non-participants. The 
reasons for non-participation are typically: subject refusal, subjects deceased or too ill, 
subject unreachable for some reason, subject unable to speak the local language, subject 
not contacted due to medical source obstacles (e.g. this might refer to a physician 
refusing access to a patient, or a member of medical staff failing to contact the patient). In 
a case-control study we endeavour to obtain data from a representative sample of cases in 
the study base and a representative sample of non-cases in the study base, conditional on 
certain covariates (54). Exclusion of any of the subsets of non-participants, whether 
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among cases or controls, could lead to biased estimates of risk, and they will if the 
prevalence of exposure to the risk factor of interest differs by subset. Thus, in the absence 
of knowledge of exposure prevalence among all those subsets, one should endeavour to 
include them all, and failure to do so represents a threat to validity of the study’s findings. 
Thus, the denominator for computing response rate should include all of the subsets of 
non-respondents listed above. The one exception to this rule is that if the study base can 
be legitimately redefined to exclude subjects in any of the subsets, and if that subset can 
be completely excluded from the study, then that subset does not need to be included in 
the denominator (or numerator) of response rate. Among the subsets listed above, the 
only one that could legitimately satisfy such criteria is the language problem subset. 
Consequently in assessing quality of reporting, we adopt the following definition of a 
response rate:                      
 
Response Rate Reporting Quality Measurement 
We examined the time trends of response rate reporting for the case, medical 
source control and population control series separately in our surveyed studies. In order 
for a reader to fully understand what the reported response rate in a paper truly means, it 
is necessary to know how the authors dealt with each of the components of ―eligible 
subjects‖ in the above formula. We created a scoring system to evaluate the quality of 
reporting of subject response rate; we assigned to each of these five components a 
reporting quality rating of either “low”, “medium”, or “high”. This rating was defined 
as: ―low‖ = no information was provided in the study on this component and it cannot be 
calculated from information provided; ―medium‖ = some information was provided, 
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either explicitly or implicitly, that permitted an estimate of this component, but there was 
some ambiguity in the information that detracted from certainty (e.g., a response rate was 
provided but the number of eligible subjects was unknown); ―high‖ = there was clear 
explicit information that allowed for an estimation of this component with high 
confidence (e.g., the number of eligible subjects and the response rate or the total number 
of participants were both explicitly provided). 
In addition to assigning a quality rating for each component of response rate 
calculation of a study, we created an overall quality score to represent each study’s 
overall response rate reporting quality. This score represents a study’s overall 
presentation of number of true eligible subjects, number of true participants and true 
response rate. It is an ordinal score ranging from ―0‖ to ―3‖; Score ―0‖ indicates that no 
information was provided on subject participation; ―1‖ indicates that there were 
information provided on eligible subjects and total participants, but no information was 
provided on reasons for non-participation; ―2‖ indicates that there was information 
provided on eligible subjects, total participants,  and some information on reasons for 
non-participation; and ―3‖ indicates that there was comprehensive information provided 
on subject participation, including information on eligible subjects, total participants, and 
all 4 possible reasons for non-participation: subject refusal, subject deceased or too ill, 
subject unreachable, and medical source obstacle (when appropriate). 
Results 
 This review included 370 case-control studies of cancer (Figure 1). We excluded 
three journals due to a lack of published studies meeting our inclusion criteria. As shown 
in Table 1, one general epidemiology and three cancer journals accounted for nearly 80% 
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of the studies meeting the inclusion criteria. There were approximately equal numbers of 
studies selected in the years representing each decade of publication, except for a bulge in 
2005. The most studied cancer types were breast, cervix or endometrial cancers (22%), 
lung, mesothelioma or respiratory tract cancers (11%), and hematopoietic cancers (10%).  
Two-thirds of studies were conducted in North American populations with the rest spread 
in the other eligible regions. The median year of data collection ranged from 1961 to 
2010, with a large majority (37%) of studies occurring between 1991-2000. 51 of the 370 
studies used multiple control series in their studies, yielding a total of 370 case series and 
422 control series in our data. Of these control series, 66% were selected from the general 
population, 31% were selected from medical sources (hospitals, clinics, HMO or GP lists, 
and cancer or death registers) and 3% were selected from friends and/or family of cases. 
Because such a small number of studies used friend or family controls, we did not include 
these in our analyses. As for mode of data collection, 69% of studies collected data from 
subjects in person, 10% through mail, 8% through telephone, and 12% through multiple 
methods. 80% of studies only interviewed subject respondents; nearly all the rest 
accepted proxy response.  
Whether or not financial incentives were used to encourage subject participation 
was rarely reported (<3%). The same was true regarding the reporting of persons 
responsible for soliciting subjects’ participation (6%). Among the 364 applicable case 
series, only 30% reported their eligibility criterion on non-participants due to medical 
source obstacles, and among those, 79% considered those non-participants as eligible for 
purposes of computing response rates. Among the 126 applicable medical source series, 
only 10% reported their eligibility criterion on non-participants due to medical source 
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obstacles, and among those, 58% considered those non-participants as eligible for 
purposes of computing response rates.   
Quality of reporting of response rates 
The overall quality score of response rate reporting in the case, medical source 
control, and population control series are presented by publication year in Table 2.  
The case and population control series had a very similar pattern for overall 
quality of response rate reporting. 16% and 13% of studies had an overall quality score of 
―0‖, for the reporting of the case and population control series, respectively. Of the 
remaining studies, in both series, the proportion of studies declined as the score 
increased. Only 12% and 11% of studies had an overall quality score of ―3‖, for the 
reporting of the case and population control series, respectively. In addition, time trends 
for the reporting of these two series showed a decline in studies with a score of ―0‖ and 
―2‖, an increase in studies with a score of ―1‖, and a peak in 1995 publications in studies 
with a score of ―3‖. The pattern of overall quality of response rate reporting for the 
medical source control series differed from that for the case and population control series. 
Nearly half of such studies had an overall quality score of ―0‖. Few of the reports of the 
medical source control series had scores greater than or equal to ―2‖. Moreover, despite 
some fluctuations, the pattern of response rate reporting for the medical source control 
series did not seem to have changed over time. 
Further, we subdivided the case series into those from studies in which population 
controls were exclusively used and those from studies in which medical source controls 
were exclusively used. Interestingly, the quality of the reporting regarding cases was 
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better when the study used population controls than when medical source controls were 
used (see Appendix Table A). 
The reporting of response rates and each component of reasons for non-
participation for the case, medical source control and population control series is 
presented in Table 3. Overall, reporting quality for both response rates and reasons for 
non-participation were the highest in cases, followed by population controls, and lastly by 
medical source controls. 60%, 52% and 31% of studies had a ―high‖ quality rating for the 
reporting of response rates, for the case, population control and medical source control 
series, respectively. For the reporting of reasons for non-participation, each component 
was more often reported for the case series than for the population and medical source 
control series. Subject refusal was the most reported reason for non-participation in all 
three series. 
As we did in relation to overall quality, we compared the components of quality 
between cases from studies that used exclusively population controls with those that used 
exclusively medical source controls. As shown in Appendix Table B, the reporting of 
response rate and other components were worse for cases in medical-source-based than in 
population-based studies.  
Discussion 
There was rather poor reporting of relevant information on subject response rates in 
case-control studies of cancer, especially regarding reasons for non-participation. In 
addition, subject eligibility criteria were often unclear. Although the proportion of studies 
not reporting any information on response rates has declined slightly over time, overall 
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reporting quality did not seem to have improved substantially. There was a tendency for 
better quality of reporting in case series, followed by population control series, and lastly 
by medical source control series. Further, the authors of studies using population controls 
were more assiduous in their reporting practices than authors of studies using medical 
source controls. This latter phenomenon may be partly explained by two factors. There 
were proportionately more population-based controls used in more recent years, and 
perhaps this just reflects a temporal trend in quality of reporting. A second conjecture is 
that there has been a tendency for investigators with clinical research credentials to be 
more likely than investigators with epidemiology credentials to have undertaken 
proportionately more studies using medical source controls.  
It seems that many authors did not have a clear understanding of the distinction 
between ―response rate‖, ―participation rate‖, and ―cooperation rate‖, as the terms were 
often used interchangeably. This problem is particularly apparent in studies for which full 
subject eligibility could not be ascertained at the initial stage, such as in studies using 
random digit dialing. For example, some studies would calculate the overall response rate 
by multiplying the screening response rate and the interview response rate while other 
studies would simply refer to the interview response rate as the overall response rate (17). 
While it is reasonable to exclude ineligible subjects from the denominator of response 
rate; it is, however, difficult to define correctly and consistently ―eligibility‖. For 
example, Harris (19) pointed out in her commentary that some studies tended to exclude 
deceased and unreachable subjects from the denominator of response rate while other 
studies did not. The consequence of having different definitions of eligibility in common 
usage can be detrimental. As Nattinger et al. (44) demonstrated, changing the definition 
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of ―eligible subject‖ could modify their subject response rate from 57% to 70%. In the 
context of case-control studies of cancer where the sampling frame usually differs 
between case and control series, poorly or incorrectly defined eligibility criteria for cases 
and controls could cause an unpredictable level of selection bias and threatens a study’s 
generalizability, despite a reported high response rate. 
We observed different levels of reporting for subject eligibility due to medical 
source obstacles between case and medical source control series. Despite a general lack 
of reporting, more studies reported this eligibility criterion for cases than for medical 
source controls. Reports about case series were more likely to acknowledge and properly 
report obstacles in subject ascertainment due to medical personnel than were reports 
about medical source controls (79% and 58% of studies, respectively). Authors may be 
more assiduous in reporting about cases than controls.  This may be a growing problem 
as the requirements of ethical review bodies increasingly restrict access of researchers to 
human subjects without some type of intercession by medical personnel (14, 20, 25, 44). 
Since medical personnel are already overworked, it is problematic to have to rely on them 
to recruit subjects for epidemiologic research. The nature and quality of such intervention 
is not easily controllable by the researchers, and this leads to losses of potential subjects, 
and perhaps to losses of unrepresentative samples of subjects (42, 43). We do not 
consider subjects not interviewed due to language reasons an essential component of 
response rate, since the study base can legitimately be defined as members of the 
population who speak the local language, without compromising internal validity; 
however such exclusion has to be performed equivalently for cases and controls. 
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Although the current reporting of response rates in case-control studies of cancer 
is better than that in the 1980s, the proportion of 2013 studies reporting their response 
rates was still relatively low, and it was much lower than what was observed in 1995. 
Some commentators (16, 20, 55) have opined that the lack of reporting of response rates 
and of the methods used to calculate it is due to the popular perception that studies with 
low response rates are inferior to studies with higher rates. Consequently, authors would 
feel pressure to avoid presenting explicit information that could decrease their chance of 
being published. For example, one study  (55) surveyed the chief editors from 18 journals 
and found out that none of the journals had a formal policy for the reporting of study 
participation or a required minimal response rate for publication, although one editor 
asserted that studies with response rates below 60% were rarely published in their 
journal. Another potential factor in the self-censoring of information regarding response 
rates is word count limit for many journals, especially the relatively high impact journals. 
In the fierce competition for space in a manuscript, the authors may well sacrifice the 
apparently dry and potentially harmful information about their response rates for 
information about the study’s substantive findings, an unfortunate trade-off. However, 
some journals have acknowledged this issue and are trying to resolve it. For example, one 
journal editor (56) encouraged authors to use online supplementary appendices to provide 
full disclosures of subject response rates and reasons for non-participation. 
Previous studies reported that 56% (16) of case-control studies and 47% (50) of 
all epidemiologic studies provided no information regarding their response rates. In our 
sample, the proportions of studies providing no information were lower. This could be 
due to the fact that we also reviewed and extracted information on study participation 
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from previous methodological publications of our surveyed studies. Our findings were in 
line with another study that examined the reporting of response rate in 117 survey studies 
published from 34 medical journals (51). Similar to us, they reported that 76% of their 
surveyed studies provided at least some information on subject response rates, but a 
majority of them (87%) did not report clearly how the rate was calculated and did not 
provide reasons for non-participation. In addition, in keeping with Morton et al.’s finding 
(16), we also observed that population-based case-control studies tended to report more 
often information on response rates than did medical-source-based studies. Our findings 
on the overall quality of response rate reporting showed that, over time, although fewer 
studies reported no information on this parameter, most studies still only reported 
minimal information on response rates. Moreover, we observed that the quality of 
reporting seemed to peak in our 1995 sample. We hypothesize that it improved up to that 
point because of increasing awareness of the importance of response rate as a contributor 
to study quality, and it declined afterwards because of the reasons alluded to above, 
namely, the increase in subject refusal and the increasing difficulties in accessing subjects 
due to ethical constraints leading to declining response rates, resulting in a greater 
reluctance to reveal the true response rates to journal editors and reviewers, coupled with 
increasing pressure on word counts. Nor did we observe much in the way of elucidation 
of methods used to enhance participation, such as  the role or title of the person in charge 
of soliciting subject participation and the use of financial incentives, both of which may 
influence subject’s response rate (14, 15, 18, 27). While such information is not essential 
to deriving a true response rate, it nevertheless would be useful to understand reasons for 
     49 
 
particularly high or low response rates and could inform researchers contemplating new 
studies.   
There are a few considerations that may affect the interpretation of our study. 
First, as there is no consensus in how response rate should be calculated and reported, 
others may find that our definition, which includes the major sources of nonresponse in 
the denominator, is too conservative or rigid. Second, we selected for this review 15 
journals that in our view were likely to have published a large fraction of epidemiological 
case-control studies of cancer. There have been other journals, but in our view these 
would not have accounted for large numbers of articles of the types we were searching 
for, and in any case, the journals we selected probably represent the ―best case scenarios‖ 
of high quality epidemiology journals. Articles published elsewhere may well have been 
of lower quality on average. Our focus on case-control studies of cancer, rather than on a 
broader tableau of possible designs and content areas has both pros and cons. Although it 
does not provide an overview of the reporting of response rates in epidemiologic studies, 
we were able to explore the practice of response rate reporting in this paradigm in depth 
and ensure that our findings over time are not confounded by shifting proportions of 
study designs or disease outcomes.  In addition, our large sample size comprised of 
studies published in the past three decades enabled us to explore in detail the current and 
past practice of reporting of response rates and reasons for non-participation. 
Conclusion 
Response rates have not been well or consistently reported, in case-control studies 
of cancer. Given the perceived decline of subject participation in case-control studies of 
cancer, the lack of transparency in reporting and consistency in calculating response rate 
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make it difficult to properly take stock of the situation.  Although efforts have been made 
to improve the overall reporting quality of observational epidemiologic studies through, 
for example, the publication of Strengthening the Reporting of Observation Studies in 
Epidemiology (STROBE) statement (31, 57), the impact of such initiatives is yet to be 
manifested.  It would be helpful for a consensus to emerge regarding the reporting and 
calculation of response rate, based on the principle of maximal disclosure.
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Table 1. Frequency distributions of the surveyed studies 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No.n % 
All 370  
Journal   
CEBP 83 22.4 
AJE 71 19.2 
CCC 68 18.4 
IJC 63 17.0 
Others
1  85 23.0 
Publication year   
1984-1986 75 20.3 
1995 83 22.4 
2005 140 37.8 
2013 72 19.5 
Cancer type   
Breast, cervix, endometrium 83 22.4 
Lung, mesothelioma, respiratory tract 42 11.4 
Hematopoietic 36 9.7 
Prostate, testicle, penis 32 8.6 
Head and neck 30 8.1 
Colorectum 28 7.6 
Bladder, kidney, urinary tract 27 7.3 
Ovary 23 6.2 
Stomach, liver, pancreas 22 5.9 
Skin 16 4.3 
Brain 15 4.1 
Others 16 4.3 
Study population   
North America (USA  and Canada) 245 66.2 
Southern Europe
2 
51 13.8 
Northern Europe
3 
41 11.1 
Eastern Europe
4 
8 2.2 
Australia or New Zealand 16 4.3 
Multiple 9 2.4 
Median year of data collection   
1961-1980 63 17.0 
1981-1990 103 27.8 
1991-2000 138 37.3 
2001-2010 59 15.9 
Not mentioned 7 1.9 
Type of control series
5   
Population 
6 
278 65.9 
Medical source
7 
131 31.0 
Friends and family 13 3.1 
Mode of data collection   
In-person 256 69.2 
Mail 36 9.7 
Telephone 31 8.4 
Multiple methods 43 11.6 
Not mentioned 4 1.1 
Type of respondent accepted   
Self only 297 80.3 
Proxy only 6 1.6 
Self and proxy 64 17.3 
Not mentioned 3 0.8 
Use of Financial incentives   
Yes 8 2.2 
No 1 0.3 
Not mentioned 361 97.6 
Persons soliciting participation   
Research team 14 3.8 
Medical personnel 7 1.9 
Not mentioned 349 94.3 
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1. All other journals listed in Figure 1, except for Prostate, Lung Cancer and Journal of 
Epidemiology and Community Health, which had no studies meeting the inclusion criteria. 
2. Southern Europe:  Spain, Portugal, Italy, Greece, France. 
3. Northern Europe:  Finland, Sweden, Norway, Denmark, Netherlands, including Germany and     
United Kingdom. 
4. Eastern Europe: Russia, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, 
Turkey, Slovenia. 
5.   The sum of the percentage of each type of control series do not add up to 100 because some 
studies used more than one type of control series. 
6. Includes sources such as population registers, electoral lists, random digit dialing, driver’s 
license, governmental medical insurance lists and neighbors of cases. 
7. Includes such sources as hospital or clinic patients, HMO or GP lists, and cancer or death 
registers. 
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Table 2. Overall quality of response rate reporting in surveyed studies by publication year, and by type of subject series (case series, 
medical source control series, population control series) 
 
 
 
 
 
 
 
 
 
 
 
* The overall score represents a study’s overall presentation of number of true eligible subjects, number of true participants and true response rate. 
The scores are assigned with an ordinal score from 0 to 3 (0 being the least informative). 
0: No information on subject participation 
1: Information provided on eligible subjects and participants, but no information on reasons for non-participation 
2: Information provided on eligible subjects, participants, and some information on reasons for non-participation 
3: Comprehensive information on subject participation (provide information on participants and all 4 reasons for non-participation including subject refusal, 
medical source obstacle, subject deceased or too ill, and subject unreachable, so the number of eligible subjects could be calculated as the sum of participants and 
non-participants if it was not given explicitly)   
Overall score 
(Range: 0-3*) 
Publication year 
1984-1986 1995 2005 2013 Overall 
n (%) n (%) n (%) n (%) n (%) 
Cases  
0 18 (24.0) 13 (15.7) 17 (12.1) 10 (13.9) 58 (15.7) 
1 21 (28.0) 29 (34.9) 61 (43.6) 38 (52.8) 149 (40.3) 
2 33 (44.0) 26 (31.3) 44 (31.4) 16 (22.2) 119 (32.2) 
3 3 (4.0) 15 (18.1) 18 (12.9) 8 (11.1) 44 (11.9) 
Total 75 (100) 83 (100) 140 (100) 72 (100) 370 (100) 
Medical 
Source 
Controls 
0 19 (46.3) 12 (44.4) 22 (44.0) 7 (53.8) 60 (45.8) 
1 11 (26.8) 11 (40.7) 17 (34.0) 4 (30.8) 43 (32.8) 
2 10 (24.4) 4 (14.8) 11 (22.0) 2 (15.4) 27 (20.6) 
3 1 (2.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8) 
Total 41 (100) 27 (100) 50 (100) 13 (100) 131 (100) 
Population 
Controls 
0 8 (21.1) 7 (10.8) 12 (11.4) 9 (12.9) 36 (12.9) 
1 15 (39.5) 32 (49.2) 65 (61.9) 43 (61.4) 155 (55.8) 
2 12 (31.6) 17 (26.2) 15 (14.3) 13 (18.6) 57 (20.5) 
3 3 (7.9) 9 (13.8) 13 (12.4) 5 (7.1) 30 (10.8) 
Total  38 (100) 65 (100) 105 (100) 70 (100) 278 (100) 
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Table 3. Quality of reporting of information on components of response rates in surveyed studies, by type of subject series (case 
series, medical source control series, and population control series) 
 a. The quality rating was based on a review of the paper by MX. The general algorithm was: Low = no information is provided in the paper on this 
component and it cannot be calculated from information provided; Medium = some information is provided, either explicitly or implicitly, that permits an 
estimate of this component, but there is some ambiguity in the information that detracts from certainly; High = there is clear explicit information that 
allows for an estimation of this component with high confidence. 
b. The values in this column represent the percentage of studies that fall into these quality categories. 
c. The information needed to ascertain the response rate is the denominator (eligible subjects) and the numerator (participants). But this is not enough if the 
authors have not made it clear how they dealt with various reasons for non-participation. It should be evident to the reader how many subjects did not 
participate, by reasons for non-participation, and how these subjects were dealt with in defining the ―eligible subjects‖. 
d. This could include the patient’s physician refusing access to the patient, or the medical staff being unable to carry out a gatekeeper function. 6 case series 
and 5 medical control series were excluded because only the proxies of deceased subjects were interviewed. 
e. This could include the subject was deceased or too ill and no proxy was allowed or found.
 Cases Medical source controls Population controls 
 n=370 series n=131 series n=278 series 
 Quality
a
 Quality
a
 Quality
a
 
 Low
b
 Medium
b
 High
b
 Low Medium High Low Medium High 
 n (%)  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Information provided 
c
          
Eligible subjects 148 (40.0)  222 (60.0) 88 (67.2)  43 (32.8) 132 (47.5)  146 (52.5) 
Total participants 58 (15.7) 93 (25.1) 219 (59.2) 60 (45.8) 30 (22.9) 41 (31.3) 36 (12.9) 98 (35.3) 144 (51.8) 
Non-participation reasons          
Subject refusal 239 (64.6) 24 (6.5) 107 (28.9) 102 (77.9) 15 (11.5) 14 (10.7) 200 (71.9) 12 (4.3) 66 (23.7) 
Medical source obstacle
d
 279 (76.6) 8 (2.2) 77 (21.2) 127 (96.9) 1 (0.8) 3 (2.3) - - - 
Subject deceased or too ill
e 
262 (70.8) 12 (3.2) 96 (25.9) 123 (93.9) 0 (0.0) 8 (6.1) 237 (85.3) 3 (1.1) 38 (13.7) 
Subject unreachable 279 (75.4) 7 (1.9) 84 (22.7) 122 (93.1) 0 (0.0) 9 (6.9) 218 (78.4) 7 (2.5) 53 (19.1) 
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Figure 1. Surveyed study selection method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Study base 
Surveyed journals: 
 American Journal of Epidemiology 
 International Journal of Epidemiology 
 American Journal of Industrial Medicine 
 American Journal of Public Health 
 Epidemiology 
 Occupational and Environmental Medicine (formally named British Journal of 
Industrial Medicine) 
 Cancer Epidemiology, Biomarkers & Prevention 
 Journal of Occupational and Environmental Medicine 
 Nutrition and Cancer 
 Scandinavian Journal of work, Environment & Health 
 International Journal of Cancer 
 Cancer causes &Control 
 Prostate 
 Lung Cancer 
 Journal of Epidemiology and Community Health 
Surveyed publication years: 
 1984-1986, 1995, 2005, 2013 
 
 
Surveyed studies (n = 370) 
Including: 
 Case series: n=370 
 Population control series: n=278 
 Medical source control series: n=131 
 Friends and family control series: n=13 
 
 
Inclusion criteria for published studies: 
 Case-control studies of etiological risk factors of cancer conducted in 
subjects aged 18+ 
 Data collected from subjects or proxy respondents using survey 
instruments 
 Studies conducted in North America, Europe, Australia, or New Zealand 
Exclusion criteria for published studies: 
 Nested case-control and case-cohort studies 
 Studies using information obtained solely from data linkage 
 Studies with less than 50 subjects per case or control series 
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Appendix Table A. Overall response rate reporting quality of the case series in surveyed studies by publication year presented 
separately for studies that used exclusively medical-source-based controls and population controls. 
 
 
 
 
 
 
 
 
 
* The overall score represents a study’s overall presentation of number of true eligible subjects, number of true participants and true response rate. 
The scores are assigned with an ordinal score from 0 to 3 (0 being the least informative). 
0: No information on subject participation 
1: Information provided on eligible subjects and participants, but no information on reasons for non-participation 
2: Information provided on eligible subjects, participants, and some information on reasons for non-participation 
3: Comprehensive information on subject participation (provide information on participants and all 4 reasons for non-participation including 
subject refusal, medical source obstacle, subject deceased or too ill, and subject unreachable, so the number of eligible subjects could be calculated 
as the sum of participants and non-participants if it was not given explicitly)  
 
Case series 
Overall score 
(Range: 0-3*) 
Publication year 
1984-1986 1995 2005 2013 Overall 
n (%) n (%) n (%) n (%) n (%) 
In studies using 
exclusively 
medical-source-
based controls 
0 13 (40.6) 10 (40.0) 11 (28.9) 5 (45.5) 39 (36.8) 
1 11 (34.4) 10 (40.0) 16 (42.1) 2 (18.2) 39 (36.8) 
2 8 (25.0) 5 (20.0) 11 (28.9) 4 (36.4) 28 (26.4) 
3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Total 32 (100) 25 (100) 38 (100) 11 (100) 106 (100) 
In studies using 
exclusively 
population-
based controls 
0 2 (7.4) 1 (1.9) 3 (3.6) 4 (7.1) 10 (4.6) 
1 6 (22.2) 18 (34.0) 34 (41.0) 33 (58.9) 91 (41.6) 
2 16 (59.3) 20 (37.7) 29 (34.9) 12 (21.4) 77 (35.2) 
3 3 (11.1) 14 (26.4) 17 (20.5) 7 (12.5) 41 (18.7) 
Total 27 (100) 53 (100) 83 (100) 56 (100) 219 (100) 
 61 
 
Appendix Table B. Reporting quality of information on components of response rates of the 
case series in surveyed studies, presented separately for studies that used medical-source-based 
controls and population controls.  
 
a. The quality rating was based on a review of the paper by MX. The general algorithm was: Low = no 
information is provided in the paper on this component and it cannot be calculated from information 
provided; Medium = some information is provided, either explicitly or implicitly, that permits an estimate of 
this component, but there is some ambiguity in the information that detracts from certainly; High = there is 
clear explicit information that allows for an estimation of this component with high confidence. 
b. The values in this column represent the percentage of studies that fall into these quality categories. 
c. The information needed to ascertain the response rate is the denominator (eligible subjects) and the 
numerator (participants). But this is not enough if the authors have not made it clear how they dealt with 
various reasons for non-participation. It should be evident to the reader how many subjects did not 
participate, by reasons for non-participation, and how these subjects were dealt with in defining the ―eligible 
subjects‖. 
d. This could include the patient’s physician refusing access to the patient, or the medical staff being unable to 
carry out a gatekeeper function. This component only applies to 364 studies in the case series because in 6 
studies only the proxies of deceased subjects were interviewed. 
e.         This could include the subject was deceased or too ill and no proxy was allowed or found. 
 
 
Case series 
 
In studies using exclusively 
medical-source-based controls 
In studies using exclusively 
population-based controls 
 n=106 series n=219 series 
 Quality
a
 Quality
a
 
 Low
b
 Medium
b
 High
b
 Low Medium High 
 n (%)  n (%) n (%) n (%) n (%) n (%) 
Information provided 
c
       
Eligible subjects 69 (65.1)  37 (34.9) 57 (26.0)  162 (74.0) 
Total participants 39 (36.8) 31 (29.2) 36 (34.0) 10 (4.6) 48 (21.9) 161 (73.5) 
Non-participation reasons       
Subject refusal 80 (75.5) 14 (13.2) 12 (11.3) 130 (59.4) 8 (3.7) 81 (37.0) 
Medical source obstacle
d
 97 (97.0) 1 (1.0) 2 (2.0) - - - 
Subject deceased or too ill
e 
101 (95.3) 1 (0.9) 4 (3.8) 129 (58.9) 10 (4.6) 80 (36.5) 
Subject unreachable 102 (96.2) 0 (0.0) 4 (3.8) 146 (66.7) 7 (3.2) 66 (30.1) 
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Abstract 
Low subject participation increases the potential of selection bias in case-controls studies, 
which in turn may weaken the validity of risk estimates. There is concern that response rate in 
epidemiologic studies has declined over the past decades. To assess this issue in case-control 
studies of cancer and to identify study design determinants of response rate, the authors 
conducted a review of data from 370 case-control studies of cancer published in 15 
epidemiology, public health, or general medical journals during four periods: 1984-1986, 1995, 
2005, and 2013. Univariate linear regression models were used to analyse time trends of 
response rate in studies conducted during 1971-2010. Multivariate linear regression models 
adjusted for time and other study design factors were used to examine study design determinants 
of response rate. Participation has declined over the past 30 years, and this decline was steeper in 
studies conducted after 2000. When compared to the response rates in the period of 1971-1980, 
there was a greater decline of this rate in population controls (-17.04%, 95% CI: -23.17%, -
10.91%) than in cases (-5.99%, 95% CI: -11.50%, -0.48%). Statistically significant study design 
determinants for cases’ participation were cancer type examined, location of study population, 
and mode of data collection. The only determinant for medical source controls’ participation was 
location of study population, and the only determinant for population controls’ participation was 
type of respondent accepted. The authors conclude that response rates in case-control studies of 
cancer seem to have declined and this decline has accelerated in recent studies, especially among 
population controls, which threatens the credibility of results derived from case-control studies 
of cancer.  
Key words:  case-control studies; cancer, epidemiologic methods; response rate; participation 
rate, data collection 
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Introduction  
The case-control study design is the most practical and efficient design to examine the 
causal relationship of exposures to rare diseases with long induction period such as cancer, and it 
has contributed greatly in improving our understanding of the etiology of this disease (2, 58). To 
ensure the internal validity of a case-control study, we aim to enroll representative samples of 
cases and of controls from the same source population. The selected controls should provide an 
unbiased  estimate of prevalence of exposure and covariates in the source population that gave 
rise to the cases (3, 59). Selection bias occurs when this principle is violated. One form of such 
bias is nonresponse bias, which arises when participation is differential by exposure and by 
disease status (3). Although case-control studies with low subject response rates do not 
necessarily produce biased risk estimates, they are more susceptible to nonresponse bias than 
studies with higher participation. It is widely believed that subject response rates in 
epidemiologic studies have declined over the last decades (14); however, the magnitude and 
reasons of this change, and whether it is present in all epidemiological study designs are still 
unclear. Previous time trend assessments of response rates in epidemiologic studies were 
impeded by insufficient reporting of subject participation and inconsistent methods for response 
rate calculation in published studies. Moreover, there has been little investigation of this 
phenomenon in the past decade. 
We therefore conducted a review of studies published from 1984-2013 to assess the time 
trends of response rates in case-control studies of cancer and to examine study design factors that 
are associated with this rate. 
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Materials and methods 
Sample selection  
This is a review of questionnaire-based case-control studies of cancer that were published 
over the past 30 years. In a preliminary exercise we established that PubMed and other automatic 
search methods were not reliable in identifying all case-control studies, and even less, in 
identifying those that reported response rates. We realized that we would have to review all 
articles in certain journals one-by-one. Given the enormous number of studies in all journals and 
the practical limitation of being able to review them all, we instituted a strategy to restrict 
numbers but yet maintain relevance. Based on our large bank of reprints of cancer case-control 
studies published since the 1980s, we identified fifteen international journals of epidemiology, 
public health and general medicine that seemed to be the main vehicles for publication of 
epidemiological studies of cancer during this period. Some of the selected journals did not exist 
for the entire period. We further restricted attention to articles published in certain calendar years 
in each decade, namely 1984-1986, 1995, 2005, and 2013. For those selected journals and those 
years, we ―manually‖ examined each issue and each article, and selected those that satisfied the 
following additional inclusion criteria: 1) Samples were restricted to case-control studies 
focusing on cancer etiology in adults. 2) Four sub-periods of publication were selected: 1984-
1986, 1995, 2005, and 2013. A 3-year period was selected to represent the mid-1980s because of 
the small number of studies per year before 1990. 3) Studies had to be conducted in North 
America, Europe, Australia, or New Zealand. 4) Studies had to have adopted the classic case-
control design; nested case-control or case-cohort studies were excluded. 5) Studies had to 
include at least 50 cases or 50 controls in the studies, so as to minimize statistical instability of 
parameters of interest. 6) Studies had to entail data collection from subjects or their proxy 
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respondents using questionnaire instruments; pure record linkage studies were excluded. 7) If 
multiple publications were produced based on the same case and control series, only the latest 
publication was included. If subject participation information was not mentioned in the selected 
publication, we sought relevant information from other reports by the study team. Figure 1 shows 
the flowchart of study sample selection. 
Data collection 
Two reviewers (MX and SC) independently screened every article in every issue of each 
journal in the targeted years, using the above criteria for inclusion. There was a virtually perfect 
concordance between the reviewers. This was a qualitative informal comparison. In the rare case 
of uncertainty, the two reviewers consulted each other or selected members of the team to 
achieve consensus decision on eligibility. For all eligible studies, we extracted journal name; 
publication year; data collection period; location of the studied population; examined cancer type 
(categorized based on cancer cell morphology and patient survival rate); types of control series 
(population, medical-source, and friends and family control series); mode of data collection (in-
person, mail, telephone, or multiple methods); types of respondent accepted (self only, proxy 
only, or self and proxy); and biologic sample collection ( Invasive methods, non-invasive 
methods, none). For each reported case and control series, we extracted information on response 
rates and reasons for non-participation.  
Response rate calculation  
The response rate of a study is calculated as the number of participants divided by the 
number of eligible subjects (20). Although theoretically straightforward, there is no standardized 
definition of what constitutes an ―eligible‖ subject in epidemiologic studies (19). In a case-
control design, we aim to obtain subjects from a representative sample of the source population, 
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and the controls should be from the same study base as the cases, conditional on certain 
covariates (59). Exclusion of non-respondents for any reason, whether among cases or controls, 
could lead to biased risk estimates if participation differs by exposure and by disease status. The 
reasons that may cause non-participation in a case-control study are: subject refusal, subject 
deceased or too ill, subject unreachable, subject unable to speak the local language and when 
appropriate, subject not contacted due to medical source obstacle(s).  (This refers to physicians 
refusing access to their patients, or that members of medical staffs failing to contact the patients.) 
Each of these reasons could conceivably be correlated with the exposure factor under study and 
with the disease outcome, and if the joint correlations are strong enough and if the fraction of the 
eligible subjects falling into those categories of non-participation is large enough, the 
respondents might provide a biased estimate of the true OR between exposure and disease. Thus 
all of those subgroups of non-respondents are relevant components of nonresponse and all of 
them should be documented. There is one exception however. By contrast with the other reasons, 
the inability to speak the local language criterion can be dispensed with by simply defining the 
study base in such a way as to exclude all people who do not speak the local language. This 
would require excluding them from case and control groups and from respondents and non-
respondents. While limiting generalizability of a study’s findings, it would not compromise 
internal validity. Because this is a legitimate strategy, we will consider that studies do not need to 
count non-participation due to language difficulty as a component of the denominator for 
computing response rates. The other reasons however, should be counted, and their absence will 
be noted.  
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Consequently, in order to keep the data extraction method uniform for our assessment on 
time trends of response rates in case-control studies of cancer, we adopted the following formula 
for the calculation of response rates:           
 
To the extent that the published papers provided the required data, we calculated response rates 
for each case and control series based on our formula presented above, and thus, the recorded 
response rates are not necessarily the same as the ones published by the investigators. When 
applicable, we also recorded whether studies treated non-respondents due to ―medical source 
obstacles‖ as eligible. When studies did not provide sufficient information that allowed for a 
calculation of their response rates using the above formula, we recorded the rates reported by the 
authors. 
Statistical analyses  
We examined the time trends of response rates, separately for cases and each type of 
controls, using univariate linear regression models. Response rate (the outcome variable) was 
measured as the proportion of persons who participated, and time (the predictor variable) was 
measured as the mid-point year of data collection of each study, and was categorized into 4 time 
periods (1971-1980, 1981-1990, 1991-2000, 2001-2010); the period 1971-1980 was defined as 
the reference group. Time trends of each nonresponse rate (subject refusal, deceased or too ill, 
unreachable, and medical source obstacle(s)) were also examined using similar methodology. 
We also conducted sensitivity analyses using only self-respondent response rates, since the 
quality of interview conducted with proxies might be less reliable compared to that of self-
respondents, which may result in information bias. To explore the yearly change in response 
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rates within each time period and subject series, we carried out regression analyses using a linear 
spline model. Potential study design determinants of response rate for each subject series were 
examined using a multivariate linear regression model; all of these potential determinants were 
considered as main independent variables and entered together into one multivariate model to be 
adjusted for each other and for time. Potential study design determinants of response rate 
included study population (North America / Northern Europe, or others), cancer type (only 
applicable for cases), mode of data collection (in-person, or others), type of respondent accepted 
(self only, proxy only, or self and proxy), and  biologic sample collection (invasive, non-
invasive, or none). We also describe the response rates as a function of the quality of reporting of 
response rates. The reporting quality index for each study was derived by a method described by 
Xu et al (2016) (47); it ranges from 0 (no information) to 3 (full information). 
Tests of statistical significance were two sided, with an alpha level of 0.05. Statistical 
analyses were conducted using SPSS (IBM SPSS Statistics, Version 20.0. Armonk, NY: IBM 
Corp). 
Results  
We extracted information from 370 case-control studies of cancer (Figure 1) published 
during 1984-2013 from twelve journals of epidemiology, public health and general medicine 
(three journals were excluded due to a lack of published studies meeting our inclusion criteria); 
as shown in Table 1, one general epidemiology journal and three cancer journals accounted for 
nearly 80% of the sampled studies. Study’s mid-point year of data collection ranged from 1961 
to 2010, with 37% of them conducted during 1991-2000. 51 studies used multiple control series, 
yielding a total of 370 case series and 422 control series in our data. Of these control series, 66% 
were selected from the general population, 31% were selected from medical sources and 3% 
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were selected from friends and/or family of cases. Because such a small number of studies used 
friend or family controls, we did not include these in our analyses. The most examined cancer 
types in our surveyed studies were breast, cervix or endometrial cancers (22%), lung, 
mesothelioma or respiratory tract cancers (11%), and hematopoietic cancers (10%). Two-thirds 
of studies were conducted in North American populations with the rest spread in the other 
eligible regions. 69% of studies collected data from subjects in person, with the rest collected 
data via mail, telephone, or multiple methods combined. 80% of studies only interviewed subject 
respondents; most of the remaining accepted proxy response. Biologic samples were collected in 
24% of studies; most of them collected samples via invasive methods (e.g. blood). 
Table 2 shows the median and its 25 to 75 percentile range of subject response rates in 
surveyed case-control studies of cancer by study data collection period  (not date of publication) 
and by each study design factor for cases, medical source controls and population controls, 
respectively. The overall median response rates were 77.2%, 86.8%, and 67.0%, for cases, 
medical source controls, and population controls, respectively, in studies conducted during 1971-
2010. The recent levels of median response rates in studies conducted during 2001-2010 were 
75.6%, 78.0%, and 53.0% for cases, medical source controls, and population controls, 
respectively. For all three subject series, response rates were highest before 1990, and declined in 
studies conducted after 2000. When restricted to studies that only used self-respondents 
(Appendix 1), we observed slightly lower but very similar pattern of response rates over time in 
all three subject series.  
The non-response rate for each reason for non-participation is presented in Table 3. 
Reasons for non-participation were rarely reported in publications; the most reported reason was 
subject refusal and the least reported was medical source obstacles. Subject refusal accounted for 
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the most prevalent reason for non-participation for cases (9.6%) and population controls 
(21.5%), and the most prevalent reason for medical source controls was non-participation due to 
medical source obstacles (10.3%). However, we observed a change in how authors consider the 
eligibility of non-respondent cases due to medical source obstacles and in the reporting of this 
reason for non-participation (Table 5). Over time, fewer studies reported this reason for non-
participation and even fewer considered these non-respondents as eligible. 
Of the studies that reported having requested biologic samples from all participants, the 
collection rate was only reported in 41% of studies for cases, 37% for medical source controls, 
and 32% for population controls (Table 4). The median biologic sample collection rate was 72% 
for cases, 75% for medical source controls, and 52% for population controls. There was no 
obvious time trend of this rate except for a steep decline observed in medical source controls in 
studies conducted after 2000; however, very few studies conducted after 2000 adopted the use of 
medical source controls. 
Table 6 presents the time trends of response rates from self and proxy respondents in our 
surveyed studies, by type of subject series. Overall, response rates declined over time. For cases, 
we observed a statistically significant change of -5.99% (95%CI: -11.50%, -0.48%) of response 
rate in 2001-2010, when compared to that in 1971-1980. For population controls, statistically 
significant changes of -11.07% (95%CI: -16.52%, -5.62%) and -17.04% (95%CI: -23.17%, -
10.91%) were observed in 1991-2000 and in 2001-2010, respectively. No significant decline of 
response rate was observed in medical source controls. When analyses were restricted to studies 
that only included self-respondents (Appendix 2), we observed statistically significant and 
greater (except for population controls) declines of response rates in 2001-2010, in all subject 
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series. The yearly change in response rate (self and proxy) within each time period for each 
subject series are presented in Appendix 3. 
Table 7 presents the time trends of each non-response rate. When compared to 1971-
1980, we observed statistically significant increases of subject refusal rates in 2001-2010 for 
cases and medical source controls. Statistical significant increases in subject refusal were also 
observed in the periods 1991-2000 and 2001-2010 for population controls. In addition, when 
compared to 1971-1980, we also observed statistically significant declines of non-response rates 
due to subject being unreachable for medical source controls in the periods 1981-1990 and 1991-
2000; however, these are likely due to chances since only 9 studies were included in those 
analyses. No obvious change in non-response rate was detected for other reasons. 
Table 8 presents the association between each study design factor and the response rate, 
by type of subject series. Our data shows that the study design determinants for cases’ 
participation included location of study population and mode of data collection. The only 
determinant of medical source controls’ participation was location of study population, and the 
only determinant for population controls’ participation was type of respondent accepted.  
Discussion 
Our results indicate that response rates in case-controls studies of cancer have declined 
over the past 30 years, and that this decline was steeper in studies conducted after 2000. There 
was a greater decline of response rate in control series than in cases series. Non-participation due 
to subject refusal has increased over time, especially in the population control series. We also 
observed a change in method of response rate calculation and in reporting of non-participation 
due to medical source obstacles for the case series. In addition, several study design factors, such 
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as cancer type, study population, mode of data collection, and type of respondent accepted, were 
shown to be the determinants of response rates.  
Previous review of subject participation in epidemiologic studies (14) concluded that 
societal and lifestyle changes contributed greatly to the decline of response rates in scientific 
studies over the past decades. For example, the emergence of telemarketing and political polls 
reduced the general public’s willingness to participate in scientific studies. Furthermore, longer 
working hours, and the increase in women joining the workforce also reduced subjects’ 
availability to participate in scientific research (14). In view of the social and technological 
changes, epidemiologists have started to question the effectiveness of using some traditional 
survey methods (e.g. random-digit dialing) for epidemiologic research.  
Since the 1990s concerns have been raised regarding the methods used to calculate and 
report response rates in published studies (20, 32). Previous assessments of response rate time 
trends in observational epidemiologic studies were severely impeded by a lack of reporting and a 
lack of consistency in the methods used to calculate response rates in published studies. A survey 
of researchers in the field of cancer case-control studies (20) concluded that there was a wide 
range of methods adopted to calculate response rates; moreover, it was difficult to verify whether 
the methods used to calculate this rate have changed over time since the quality of response rate 
reporting was and is still poor in published studies. In our data, a higher percentage of studies 
reported detailed information on response rates and reasons for non-participation in studies 
published in 1995 than in studies published after 2000, with only around 10% and 1% of studies 
providing sufficient information to allow for the calculation of response rate and non-response 
rate for each reason for non-participation for cases or population controls, and for medical source 
controls, respectively (data not shown). 
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We observed that with time, fewer studies reported non-participation of cases due to 
medical source obstacles and fewer considered these non-respondents eligible. There has been an 
increasing amount of restrictions imposed by ethical review bodies on researchers to access 
human subjects without medical personnel intercession (14, 25, 44). However, given that most 
medical personnel are already too occupied with their own tasks, it is problematic to rely on 
them to recruit participants for epidemiologic studies. In addition, the nature and quality of such 
intervention is not easily controllable by epidemiologists, thus this may lead to the losses of 
potential participants and of representative subject samples (42, 43). Given that, it is plausible to 
speculate that over time, researchers would report less non-participation due to medical source 
obstacles and/or exclude such non-respondents from the calculation to give the impression of 
higher response rates.  
Very few studies examined the level of subject response rates in epidemiologic case-
control studies. One study (20) compared the response rates of population controls in 2 studies 
conducted in the mid-1980s  to 2 similar studies conducted in the late 1970s or early 1980s, and 
concluded that population controls’ response rates had declined by 16-28%. Another study (33) 
demonstrated that in similar settings, the amount of researchers’ efforts needed to maintain high 
response rate in population controls had almost doubled from 1991 to 2003. Previous reviews 
have examined the time trends of response rates in surveyed case-control studies conducted 
between 1970s to the early 2000s (16, 32, 34). Two reviews (16, 32, 34) concluded that no 
significant changes in response rates were observed in studies conducted until the late 1990s, and 
one review (16) concluded that significant declines of response rates in both cases (-1.18% per 
year) and controls (-1.49% per year) were observed in 107 case-control studies conducted from 
1970-2003, with steeper but non-significant declines of response rates observed in studies 
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conducted from 1990-2003. One of the problems with earlier reviews is that they tended to rely 
on the authors’ reported response rates. But as we argued, authors have not been consistent in 
their operational definitions and have tended to exaggerate their response rates by neglecting to 
include some categories of non-participants among the eligible. We attempted to minimize this 
problem by recalculating response rates based on standardized criteria. Even this attempt may 
not have fully succeeded since we sometimes had to accept authors’ claims of their response 
rates because of the paucity of information for recalculating true response rates. We observed in 
our surveyed studies that the response rates seemed to be higher in studies with low quality of 
reporting. This might indicate that despite our attempts to recalculate true response rates in these 
studies, there was crucial information hidden from view in some publications and we were too 
generous in crediting the authors’ claims of high response rates. 
Our findings indicated that response rate did not change significantly from the 1970s to 
the 1990s, but that this rate only started to deteriorate significantly from the 2000s and the 1990s, 
for cases and for population controls, respectively. We did not observe a significant decline of 
response rates in medical source controls in studies conducted after 2000. As subject 
participation has declined precipitously for population controls but not for medical source 
controls, researchers should consider the merit of using medical source controls rather than 
population controls when planning new case-control studies of cancer. 
Given the importance of response rate in case-control studies, it is essential to understand 
its determinants. Some potential determinants are individual level characteristics like age, sex 
and education; others are study design characteristics like the type of cancer being studied, the 
location of the study, and whether biological samples were solicited. By its nature our study was 
only capable of elucidating the role of study design variables. 
 77 
 
Other investigations have demonstrated that several sociodemographic characteristics, 
such as sex, SES, education, health status, employment status, marital status, being exposed to 
the exposure of interest, and having the disease being examined, influence the likelihood of 
response  (14, 16, 29) . However, researchers have no control over these characteristics and there 
was little evidence of strategies that can be applied to all epidemiologic studies to increase 
participation via targeting sociodemographic characteristics of the sampled population (14, 30). 
On the contrary, certain study design factors can be controlled by researchers and have been 
shown to be associated with the success in enrolling subjects in epidemiologic studies. Higher 
participation were observed in studies that adopted in-person or multiple methods of subject 
recruitment and data collection, that did not require substantial commitments or invasive 
procedures, and that provided incentives. In our data, we observed the highest response rates in 
studies that interviewed subjects in person; however, using multiple methods did not improve 
subject participation, nor did we observe a decline in interview response rate or in biologic 
sample collection rate in studies involving invasive data collection. The lack of association 
between biologic sample collection and subject participation may be explained by the fact that in 
our surveyed studies, subjects were not obligated to provide biologic samples in order to 
participate in the studies. We were not able to explore the influence of incentives on response 
rates since this information was provided in 2% of the surveyed studies. In addition to the 
aforementioned study design factors, we observed that additional factors, such as location of the 
study population and type of respondent accepted also influenced the response rates in case-
control studies of cancer. 
Compared to previous time trend analyses which included 26 to 82 surveyed case-control 
studies and covered study periods until the early 2000s, we were able to examine the time trends 
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and study design determinants of response rates in studies conducted between 1971 and 2010, in 
370 surveyed case-control studies of cancer. Other than providing an updated review of the 
current level of response rate, our large sample size also allowed for the examination of reported 
reasons for non-participation and their change over time in each subject series. To account for 
inconsistencies in the methods used for response rate calculation in our surveyed studies, we 
recalculated subject response rate for each study based on standardized criteria; however, the 
lack of reporting of subject participation in surveyed studies made it difficult to calculate 
response rates in a uniform manner. Unspecified response rates and unreported reasons for non-
participation can still lead to an overestimation (or an underestimation in rare occasions) of the 
real subject response rates due to residual confounding. As there is no current consensus in how 
response rate should be calculated and reported, we are aware that others may not agree with our 
definition of response rate; however, we believe that major sources of non-participation should 
be reported and included in the calculation to reduce the potential for nonresponse bias. Authors 
should provide sufficient and transparent disclosure on study participation and leave the readers 
the freedom to interpret the validity of a study.  
Conclusion 
Response rates of case-control studies of cancer have declined over the past 30 years and 
this decline is accelerating, which increases study’s potential for selection bias. The decline is 
particularly dramatic among population controls, and it threatens the credibility of results derived 
from case-control studies of cancer.  
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TABLE 1. Frequency distributions of the surveyed studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 No.n % 
All 370  
Journal   
CEBP 83 22.4 
AJE 71 19.2 
CCC 68 18.4 
IJC 63 17.0 
Others
1  85 23.0 
Publication year   
1984-1986 75 20.3 
1995 83 22.4 
2005 140 37.8 
2013 72 19.5 
Cancer type   
Breast, cervix, endometrium 83 22.4 
Lung, mesothelioma, respiratory tract 42 11.4 
Hematopoietic 36 9.7 
Prostate, testicle, penis 32 8.6 
Head and neck 30 8.1 
Colorectum 28 7.6 
Bladder, kidney, urinary tract 27 7.3 
Ovary 23 6.2 
Stomach, liver, pancreas 22 5.9 
Skin 16 4.3 
Brain 15 4.1 
Others 16 4.3 
Study population   
North America (USA  and Canada) 245 66.2 
Southern Europe
2 
51 13.8 
Northern Europe
3 
41 11.1 
Eastern Europe
4 
8 2.2 
Australia or New Zealand 16 4.3 
Multiple 9 2.4 
Median year of data collection   
1961-1980 63 17.0 
1981-1990 103 27.8 
1991-2000 138 37.3 
2001-2010 59 15.9 
Not mentioned 7 1.9 
Type of control series
5   
Population 
6 
278 65.9 
Medical source
7 
131 31.0 
Friends and family 13 3.1 
Mode of data collection   
In-person 256 69.2 
Mail 36 9.7 
Telephone 31 8.4 
Multiple methods 43 11.6 
Not mentioned 4 1.1 
Type of respondent accepted   
Self only 297 80.3 
Proxy only 6 1.6 
Self and proxy 64 17.3 
Not mentioned 3 0.8 
Biologic sample collection   
Yes 87 23.5 
Invasive 64 73.6 
Non-invasive 23 26.4 
No 283 76.5 
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1. All other journals listed in Figure 1, except for Prostate, Lung Cancer and Journal of 
Epidemiology and Community Health, which had no studies meeting the inclusion criteria. 
2. Southern Europe:  Spain, Portugal, Italy, Greece, France. 
3. Northern Europe:  Finland, Sweden, Norway, Denmark, Netherlands, including Germany and     
United Kingdom. 
4. Eastern Europe: Russia, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, 
Turkey, Slovenia. 
5.   The sum of the percentage of each type of control series do not add up to 100 because some 
studies used more than one type of control series. 
6. Includes sources such as population registers, electoral lists, random digit dialing, driver’s 
license, governmental medical insurance lists and neighbors of cases. 
7. Includes such sources as hospital or clinic patients, HMO or GP lists, and cancer or death 
registers. 
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TABLE 2. Response rates in surveyed studies by type of subject series (case series, medical 
source control series, and population control series) 
  Response Rates (%)  
  Cases  Medical source controls Population controls  
    
 
 
n Median  25-75 
percentile 
*P-
value 
(One-
way 
ANOV
A) 
n Median 25-75 
percentil
e 
P-
value 
(One-
way 
ANOV
A) 
n Median 25-75 
percentile 
P-value 
(One-way 
ANOVA) 
Total 311 77.2 68.0‐86.0  71 86.8 75.0‐95.7  241 67.0 54.0‐75.5  
Data collection period    0.01    0.06    0.00 
1971‐20001 258 78.2 69.0‐86.2  64 87.9 75.0‐96.0  195 69.0 58.2‐76.6  
1971‐1980 50 78.2 72.0‐86.3  17 77.0 73.1‐88.5  29 75.6 62.3‐83.0  
1981‐1990 82 79.5 70.0‐88.0  18 95.0 77.0‐97.2  66 74.1 68.6‐82.6  
1991‐2000 126 76.0 65.0‐85.0  29 87.9 77.5‐96.0  100 62.9 53.8‐69.9  
2001‐2010 51 75.6 60.2‐79.5  5 78.0 50.8‐86.6  46 53.0 46.6‐67.3  
Cancer type    0.02         
Breast, cervix, endometrium 67 78.6 71.2‐82.1          
Lung, mesothelioma, respiratory 
tract 
30 83.4 73.1‐86.3          
Hematopoietic 33 72.2 59.3‐85.7          
Prostate, testicle, penis 28 75.8 69.2‐80.1          
Head and neck 24 80.9 76.0‐87.6          
Colorectum 24 70.5 65.0‐83.3          
Bladder, kidney, urinary tract 23 73.7 70.0‐86.7          
Ovary 22 71.7 60.3‐76.8          
Stomach, liver, pancreas 20 68.4 57.0‐89.8          
Skin 15 83.0 78.5‐97.1          
Brain 12 83.3 70.2‐88.5          
Study population    0.00    0.00    0.00 
North America and Northern 
Europe 
250 76.0 67.0‐82.5  36 75.1 63.5‐88.8  216 67.0 55.3‐75.1  
North America2 214 74.6 66.5‐82.0  30 75.1 66.8‐86.0  190 66.6 53.9‐75.0  
Northern Europe 3 36 79.1 74.3‐88.0  6 77.5 55.3‐92.3  26 71.0 66.8‐76.7  
Others 61 89.0 77.8‐96.2  35 95.0 86.0‐97.0  25 58.3 44.3‐77.0  
Southern Europe 4 34 95.0 85.8‐97.1  28 95.3 92.7‐98.3  5 76.1 63.0‐86.0  
Eastern Europe 5 7 86.0 83.9‐91.0  2 81.5 -  2 83.0 -  
Australia or New Zealand 15 64.3 58.1‐79.8  2 78.6 -  13 45.9 41.1‐67.9  
Multiple  5 91.3 77.9‐91.8  3 86.0 -  5 58.2 52.5‐69.7  
Mode of data collection    0.00    0.01    0.08 
In‐person 213 79.0 70.0‐87.4  58 90.3 76.5‐96.0  156 66.3 54.0‐75.0  
Others 97 74.6 61.2‐81.0  13 73.8 56.5‐84.6  85 67.1 51.6‐78.9  
Mail 30 67.4 55.7‐79.1  5 60.0 48.8‐91.0  21 63.3 41.1‐73.8  
Telephone 28 80.3 70.1‐85.8  3 80.0 -  29 71.0 59.9‐83.5  
Multiple methods 39 73.0 63.5‐83.5  5 63.9 58.2‐79.9  35 67.0 51.0‐76.6  
Type of respondent accepted    0.61    0.04    0.00 
Self only 245 76.7 67.0‐84.8  57 89.0 75.1‐96.0  191 65.0 52.2‐72.7  
Proxy only 5 74.0 59.8‐90.8  4 82.0 55.7‐94.4  0 ‐ ‐  
Self and proxy 60 80.8 69.9‐87.0  10 78.4 62.9‐86.8  50 75.1 67.0‐83.0  
Biologic sample collection    0.78    0.76    0.13 
Yes, invasive 6 58 76.1 69.9‐84.3  17 89.0 77.5‐95.3  41 64.0 56.0‐70.3  
Yes, non‐invasive 
7
 16 74.2 70.6‐82.8  3 93.0 -  14 69.0 43.7‐75.3  
No 237 78.5 67.0‐86.1  51 85.3 74.1‐96.0  186 67.9 54.0‐77.0  
Journal 
CEBP 
 
70 
 
76.6 
 
70.0‐84.1 
0.00  
17 
 
87.9 
 
67.2‐95.8 
0.14  
49 
 
66.0 
 
55.5‐73.1 
0.00 
AJE 59 78.5 66.0‐83.9  15 77.0 73.8‐88.0  43 67.0 56.6‐75.0  
CCC 60 73.6 63.5‐80.7  8 89.1 76.0‐98.0  58 56.0 45.4‐69.1  
IJC 51 84.0 73.7‐95.0  19 95.0 80.0‐97.0  31 71.9 66.0‐79.0  
Others 
8
 71 79.0 66.7‐86.0  12 82.1 69.3‐93.9  58 71.4 58.5‐78.2  
Response rate reporting score    0.00    0.07    0.79 
1 
9
 148 79.1 71.2‐88.0  43 81.0 73.8‐95.0  154 67.0 54.0‐76.0  
2 10 119 78.4 63.5‐86.0  27 93.0 83.2‐96.0  57 67.0 52.9‐73.5  
3 11 44 73.0 60.5‐76.8  1 63.4 ‐  30 65.1 49.4‐76.4  
1. One study conducted in 1961 was removed from the descriptive and analytical analyses 
2. North America: USA and Canada 
3. Northern Europe:  Finland, Sweden, Norway, Denmark, Netherlands, including Germany 
and United Kingdom 
4. Southern Europe:  Spain, Portugal, Italy, Greece, France 
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5. Eastern Europe: Russia, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, 
Turkey, Slovenia 
6. Invasive: blood sample collection 
7. Non-invasive: urine, saliva, nail or hair sample collection 
8. All other journals listed in Figure 1, except for Prostate, Lung Cancer and Journal of 
Epidemiology and Community Health, which had no studies meeting the inclusion 
criteria 
9. Score 1: Information provided on eligible subjects and participants, but no information on 
reasons for non-participation 
10. Score 2: Information provided on eligible subjects, participants, and some information on 
reasons for non-participation 
11. Score 3: Comprehensive information on subject participation (provide information on 
participants and all 4 reasons for non-participation including subject refusal, medical 
source obstacle, subject deceased or too ill, and subject unreachable, so the number of 
eligible subjects could be calculated as the sum of participants and non-participants if it 
was not given explicitly) 
* One-way analysis of variance (ANOVA) test: significance level of 0.05. 
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TABLE 3. Non-response rates in surveyed studies by type of subject series (case series, medical source control series, and 
population control series) 
*Not applicable (only proxy respondents of deceased subjects were interviewed) in 6 studies for cases and in 6 studies for medical 
source controls. 
 
  
   Non-response rates (%) 
 Cases Medical source controls Population controls 
 
No. of studies 
without 
relevant 
information 
No. of studies 
with relevant 
information 
Median 
25-75 
percentile 
No. of 
studies 
without 
relevant 
informatio
n 
No. of 
studies 
with 
relevant 
information 
Median 
25-75 
percentile 
No. of studies 
without 
relevant 
information 
No. of studies 
with relevant 
information 
Median 
25-75 
percentile 
Refusal 239 131 9.6 5.0‐13.6 102 29 5.0 4.0‐10.0 200 78 21.5 14.4‐28.9 
Deceased or too ill 262 108 8.0 4.1‐14.0 123 8 3.1 0.9‐5.8 237 41 2.0 1.0‐4.3 
Unreachable 279 91 4.0 2.0‐7.0 122 9 6.0 2.4‐8.1 218 60 7.4 3.1‐13.0 
Medical source 
obstacle* 
279 85 5.9 3.0‐10.0 121 4 10.3 4.6‐14.0 
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TABLE 4. Biologic sample collection rates in surveyed studies that requested biologic samples, by type of subject series (case 
series, medical source control series, and population control series) 
   
Biologic Sample Collection Rates (%) 
  Cases 
 
Medical source controls 
 
Population controls 
Data collection 
period 
No. of 
studies 
without 
relevant 
information 
No. of 
studies 
with 
relevant 
information 
Median 25-75 percentile 
No. of 
studies 
without 
relevant 
information 
No. of 
studies 
with 
relevant 
information 
Median 25-75 percentile 
No. of 
studies 
without 
relevant 
information 
No. of 
studies 
with 
relevant 
information 
Median 25-75 percentile 
Total 49 34 72.0 60.0-87.0 17 10 75.0 69.4-98.0 45 21 52.2 47.0-67.8 
1971‐2000 36 29 69.1 60.2-83.6 16 9 91.0 70.2-99.0 33 18 52.5 48.3-66.9 
1971‐1980 2 1 100 - 1 1 100 - 0 0 - - 
1981‐1990 7 4 81.4 70.5-97.0 0 3 98.0 - 5 2 76.3 - 
1991‐2000 27 24 64.4 56.6-77.9 15 5 73.0 70.2-94.4 28 16 52.2 48.1-65.5 
2001‐2010 13 5 77.8 50.9-91.0 1 1 45.9 - 12 3 42.3 - 
 
 
TABLE 5. Proportion of surveyed studies that considered “medical source obstacles” as an eligibility criterion for case 
recruitment, by data collection time period 
 Count as eligible Count as ineligible Lack of / insufficient information 
 No. 
%  
(by time period) 
No. 
%  
(by time period) 
No. 
%  
(by time period) 
Total 86 24.2 23 6.5 247 69.4 
1971-1980 15 25.4 2 3.4 42 71.2 
1981-1990 33 33.0 1 1.0 66 66.0 
1991-2000 31 22.5 14 10.1 93 67.4 
2001-2010 7 11.9 6 10.2 46 78.0 
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TABLE 6. Time trends of response rate in surveyed studies in which data were collected from 1971-2010, by type of subject 
series (case series, medical source control series, and population control series) 
  Cases Medical source controls Population controls 
Data collection 
period 
Difference 
(%) in 
response rate 
from 1971-
1980 
95% CI P value 
Difference 
(%) in 
response rate 
from 1971-
1980 
95% CI P value 
Difference 
(%) in 
response rate 
from 1971-
1980 
95% CI P value 
 1981-1990 1.74 -3.24, 6.72 0.49 9.17 -1.42, 19.76 0.09 0.35 -5.41, 6.11 0.90 
 1991-2000 -2.50 -7.13, 2.12 0.29 8.13 -1.30, 17.56 0.09 -11.07 -16.52, -5.62 0.00 
 2001-2010 -5.99 -11.50, -0.48 0.03 -7.10 -22.80, 8.61 0.37 -17.04 -23.17, -10.91 0.00 
 
Model: Subject response rate (%) = b0 + b1 x data collection period  
            b1: Difference (%) in response rate of each time period from 1971-1980 
            Reference group for data collection period: 1971-1980 
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TABLE 7. Time trends of non-response rates in surveyed studies in which data were collected from 1971-2010, by type of 
subject series (case series, medical source control series, and population control series) 
Non-response Rates (%) 
 
Cases Medical source controls Population controls 
Data collection period 
Difference 
(%) in 
response 
rate from 
1971-1980 
95% CI P value 
Difference 
(%) in 
response 
rate from 
1971-1980 
95% CI P value 
Difference 
(%) in 
response 
rate from 
1971-1980 
95% CI P value 
Non-response due to subject refusal 
 
1981-1990 -0.19 -3.68, 3.30 0.91 -5.64 -14.68, 3.39 0.21 2.48 -3.99, 8.95 0.45 
 
1991-2000 0.65 -2.61, 3.90 0.70 -5.01 -11.43, 1.42 0.12 11.93 5.41, 18.45 0.00 
 
2001-2010 3.95 0.03, 7.87 0.05 14.14 2.39, 25.89 0.02 10.84 3.64, 18.05 0.00 
Non-response due to subject deceased or too ill 
 
1981-1990 -4.54 -9.43, 0.35 0.07 -3.38 -11.92, 5.16 0.36 -4.67 -9.86, 0.52 0.08 
 
1991-2000 -1.58 -6.05, 2.89 0.49 -0.06 -5.89, 5.77 0.98 -2.29 -6.99, 2.42 0.33 
 
2001-2010 -3.95 -9.39, 1.48 0.15 - - - -3.08 -8.37, 2.21 0.25 
Non-response due to subject unreachable 
 
1981-1990 -1.20 -3.64, 1.24 0.33 -6.54 -12.19, -0.88 0.03 -5.23 -10.99, 0.52 0.07 
 
1991-2000 -1.92 -4.13, 0.29 0.09 -6.66 -12.31, -1.01 0.03 -1.03 -6.28, 4.22 0.70 
 
2001-2010 -0.80 -3.55, 1.94 0.56 - - - -3.16 -9.59, 3.27 0.33 
Non-response due to medical source obstacles* 
 
1981-1990 1.13 -3.66, 5.92 0.64 - - - 
   
 
1991-2000 -0.87 -5.40, 3.66 0.70 - - - 
   
  2001-2010 -0.43 -6.76, 5.91 0.89 - - -       
Models:    For all models, the data collection period of 1971-1980 was used as the reference group. 
                 Subject refusal (%) = b0 + b1 x data collection period  
                 Subject deceased or too ill (%) = b0 + b1 x data collection period 
                 Subject unreachable (%) = b0 + b1 x data collection period 
                Medical source obstacles (%) = b0 + b1 x data collection period 
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                b1 represents the difference (%) in response rate of each data collection period from the period of 1971-1980. 
               * Insufficient data for time trend analysis of non-response due to medical source obstacles in medical source controls. 
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TABLE 8. Statistical significance of the contribution of each factor as a determinant of response rates, by type of subject series 
(case series, medical source control series, and population control series) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Regression models adjusted for all presented variables and data collection period (1971-1980, 1981-1990, 1991-2000, 2001-2010). 
 
Cases Medical source controls Population controls 
Study design factors  
1
 ß
2
 95% CI for ß ß 95% CI for ß ß 95% CI for ß 
Percentage of  response rate (Constant )
3
 77.15 72.16, 82.14 77.68 69.65, 85.71 69.33 64.19, 74.46 
Cancer type (Ref:  Breast, cervix, endometrium cancers ) 
Hematopoietic -1.85 -7.65, 3.95 
    Ovary -5.10 -11.43, 1.23 
    Prostate, testicle, penis -1.34 -7.12, 4.44 
    Lung, mesothelioma, respiratory tract -0.72 -6.66, 5.23 
    Stomach, liver, pancreas -5.78 -12.58, 1.02 
    Colorectum -5.36 -11.56, 0.84 
    Bladder, kidney, urinary tract  -0.84 -7.33, 5.64 
    Head and neck  2.88 -3.48, 9.24 
    Brain ` 6.33 -2.42, 15.08 
    Skin 6.11 -1.17, 13.39 
    Others 5.34 -2.97, 13.65     
Study population (Ref:  North American and Northern European populations ) 
Other  populations 11.80* 7.92, 15.68 16.76* 9.31, 24.21 -0.97 -6.55, 4.61 
Mode of data collection (Ref:  In‐person) 
Other modes of data collection -4.78* -8.18, -1.38 -5.50 -15.87, 4.88 0.74 -2.82, 4.29 
Type of respondent accepted (Ref:  Self only) 
Proxy only  0.86 -11.30, 13.02 -2.47 -17.13, 12.18 - - 
Self and proxy 1.75 -2.60, 6.09 -4.37 -16.12, 7.37 7.39* 3.15, 11.62 
Biologic sample collection (Ref: Bio sample not collected) 
Invasive 3.34 -0.87, 7.56 3.88 -4.48, 12.23 2.189 -2.63, 7.01 
Non-invasive 2.88 -4.02, 9.79 5.86 -10.83, 22.54 -2.72 -9.96, 4.52 
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2. The ßs represent the percentage change in response rate for studies in the selected category when compared to the reference category, 
adjusted for the remaining variables.  
3. The constant represents the response rate for studies with the reference category for each variable. 
     *= significant results 
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FIGURE 1. Surveyed study selection method 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Study base 
Surveyed journals: 
 American Journal of Epidemiology 
 International Journal of Epidemiology 
 American Journal of Industrial Medicine 
 American Journal of Public Health 
 Epidemiology 
 Occupational and Environmental Medicine (formally named British Journal of 
Industrial Medicine) 
 Cancer Epidemiology, Biomarkers & Prevention 
 Journal of Occupational and Environmental Medicine 
 Nutrition and Cancer 
 Scandinavian Journal of work, Environment & Health 
 International Journal of Cancer 
 Cancer causes &Control 
 Prostate 
 Lung Cancer 
 Journal of Epidemiology and Community Health 
Surveyed publication years: 
 1984-1986, 1995, 2005, 2013 
 
 
Surveyed studies (n = 370) 
Including: 
 Case series: n=370 
 Population control series: n=278 
 Medical source control series: n=131 
 Friends and family control series: n=13 
 
 
Inclusion criteria for published studies: 
 Case-control studies of etiological risk factors of cancer conducted in 
subjects aged 18+ 
 Data collected from subjects or proxy respondents using survey 
instruments 
 Studies conducted in North America, Europe, Australia, or New Zealand 
Exclusion criteria for published studies: 
 Nested case-control and case-cohort studies 
 Studies using information obtained solely from data linkage 
 Studies with less than 50 subjects per case or control series 
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APPENDIX 1. Self-respondent response rates in surveyed studies by type of subject series 
(case series, medical source control series, and population control series) 
Self-respondent Response Rates (%) 
 Cases Medical source controls Population source controls 
 
n Median 25-75 percentile n Median 
25-75 
percentile n Median 
25-75 
percentile 
Total 286 75.5 63.4‐83.9 64 87.2 74.3‐96.0 211 64.0 52.0‐73.0 
Data collection period          
1971‐20001 235 75.0 63.5‐84.0 57 87.9 74.6‐96.0 171 66.0 56.0‐74.2 
1971‐1980 40 73.7 54.0‐84.9 14 75.1 31.1‐88.3 22 73.8 56.0‐83.0 
1981‐1990 75 76.0 63.4‐84.0 14 95.8 90.4‐98.5 54 72.0 65.5-80.0 
1991‐2000 120 74.6 64.5‐84.0 29 87.6 77.1‐96.0 95 62.4 52.8‐69.0 
2001‐2010 49 75.5 60.2‐79.1 5 78.0 50.8‐86.6 40 52.1 44.0‐67.0 
Cancer type          
Breast, cervix, endometrium 65 79.0 70.7‐82.4       
Lung, mesothelioma, respiratory 
tract 
26 71.6 52.5-84.3       
Hematopoietic 31 72.2 58.8‐83.8       
Prostate, testicle, penis 26 75.0 64.1‐80.9       
Head and neck 22 78.0 59.8-87.6       
Colorectum 23 71.0 65.0‐84.0       
Bladder, kidney, urinary tract 17 76.0 69.5-89.5       
Ovary 22 71.7 60.3‐76.8       
Stomach, liver, pancreas 16 64.0 35.8-84.0       
Skin 15 83.0 78.5-97.1       
Brain 10 73.0 21.4-81.3       
Study population          
North America and Northern 
Europe 230 73.1 62.0‐80.5 31 75.0 57.0‐87.6 190 64.8 53.0‐73.1 
North America 2 201 72.0 61.2‐79.0 28 75.0 60.4‐87.0 169 63.3 52.1‐72.4 
Northern Europe 3 29 79.1 73.8‐88.6 3 57.0 - 21 71.0 64.7-75.1 
Others 56 87.6 76.7‐96.0 33 95.0 86.0‐97.9 21 58.2 41.9‐74.0 
Southern Europe 4 32 95.0 85.7‐97.0 27 95.0 92.1‐98.8 4 74.0 58.5‐83.8 
Eastern Europe 5 7 84.1 80.4‐91.0 2 81.5 - 1 78.6 - 
Australia or New Zealand 13 63.5 57.9‐77.8 1 74.1 - 12 44.3 41.1‐63.9 
Multiple  4 89.8 87.4‐92.0 3 81.0 - 4 59.4 53.6‐73.7 
Mode of data collection          
In‐person 203 77.2 66.0‐87.0 56 90.3 77.3‐96.0 137 64.0 53.4‐73.1 
Others 83 70.0 58.1-79.1 8 50.3 30.5-71.2 74 63.1 47.8‐73.0 
Mail 23 71.0 57.7‐79.1 1 47.6 - 19 62.5 41.1‐67.1 
Telephone 24 67.4 35.7-80.5 2 30.8 - 24 68.1 51.2‐84.1 
Multiple methods 36 71.0 60.5‐76.0 5 63.4 38.0-76.5 31 62.5 50.1-71.1 
Type of respondent accepted          
Self only 245 76.7 67.0‐84.8 57 89.0 75.1‐96.0 191 65.0 52.2‐72.7 
Self and proxy 41 58.4 31.2-72.7 7 31.4 23.0-79.2 20 60.2 39.4-79.5 
Biologic sample collection          
Yes, invasive 6 56 76.0 69.3‐84.8 17 89.0 77.5‐95.3 39 64.0 43.6‐75.5 
Yes, non‐invasive 7 16 72.8 69.4‐81.1 3 93.0 - 13 69.0 11.0‐79.8 
No 214 75.2 60.9‐83.8 44 85.3 74.0‐96.0 159 64.0 52.0‐73.8 
Journal 
CEBP 
 
67 
 
76.0 
 
75.9 
 
69.1‐84.0 
 
17 
 
87.9 
 
67.2‐95.8 
 
45 
 
65.0 
 
52.5-71.3 
AJE 54 69.5 60.3‐82.0 13 75.0 47.4‐82.4 37 63.0 53.5‐74.6 
CCC 56 2 8 60.5‐80.3 7 92.1 79.2‐99.0 51 55.0 45.3‐67.0 
IJC 49 83.0 73.4‐95.0 19 95.0 80.0‐97.0 29 71.8 64.5-78.8 
Others 8 60 72.9 58.1‐81.9 8 83.2 74.3‐97.3 47 65.0 52.0-73.8 
Response rate reporting score          
1 9 137 77.2 67.5‐85.4 39 81.0 74.1‐95.7 132 65.0 53.0‐74.1 
2 10 109 73.7 60.0‐84.8 24 94.0 79.0‐96.0 53 64.6 46.4‐72.8 
3 11 40 73.6 60.1‐78.0 1 63.4 ‐ 26 60.3 46.7-71.9 
1. One study conducted in 1961 was removed from the descriptive and analytical analyses 
2. North America: USA and Canada 
3. Northern Europe:  Finland, Sweden, Norway, Denmark, Netherlands, including Germany and United Kingdom 
4. Southern Europe:  Spain, Portugal, Italy, Greece, France 
5. Eastern Europe: Russia, Poland, Czech Republic, Slovakia, Hungary, Romania, Bulgaria, Turkey, Slovenia 
6. Invasive: blood sample collection 
7. Non-invasive: urine, saliva, nail or hair sample collection 
8. All other journals listed in Figure 1, except for Prostate, Lung Cancer and Journal of Epidemiology and Community Health, which had 
no studies meeting the inclusion criteria 
9. Score 1: Information provided on eligible subjects and participants, but no information on reasons for non-participation 
10. Score 2: Information provided on eligible subjects, participants, and some information on reasons for non-participation 
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11. Score 3: Comprehensive information on subject participation (provide information on participants and all 4 reasons for non-
participation including subject refusal, medical source obstacle, subject deceased or too ill, and subject unreachable, so the number of 
eligible subjects could be calculated as the sum of participants and non-participants if it was not given explicitly)
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APPENDIX 2. Time trends of response rate in surveyed studies that only included self-
respondents and in which data were collected from 1971-2010, by type of subject series 
(case series, medical source control series, and population control series) 
 
 
Model: Self-respondent response rate (%) = b0 + b1 x data collection period  
b1: Difference (%) in response rate from 1971-1980 
Reference group for data collection period: 1971-1980 
 
 
 
 
 
  Cases Medical source controls Population controls 
Data 
collection 
period 
Difference 
(%) in 
response 
rate from 
1971-
1980 
95% CI P value  
Difference 
(%) in 
response 
rate from 
1971-
1980 
95% CI P value 
Difference 
(%) in 
response 
rate from 
1971-
1980 
95% CI P value 
 
1981-
1990 
-1.32 
-7.36, 
4.73 
0.67 6.19 
-4.39, 
16.77 
0.25 5.08 
-2.07, 
12.24 
0.16 
 
1991-
2000 
-4.77 
-10.26, 
0.72 
0.09 0.77 
-8.40, 
9.94 
0.87 -5.35 
-12.02, 
1.31 
0.12 
 
2001-
2010 
-9.67 
-16.12, 
-3.22 
0.00 -14.33 
-28.39, 
-0.26 
0.05 -12.35 
-19.70, 
-4.99 
0.00 
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APPENDIX 3. Yearly change of response rate within each time period in surveyed studies 
in which data were collected from 1971-2010, examined using a linear spline regression 
model, by type of subject series (case series, medical source control series, and 
population control series) 
 
Model
 
1
 
 Cases Medical source controls Population controls 
Data collection 
period 
β 2  95% CI 
P 
value 
β 95% CI 
P 
value 
β 95% CI 
P 
value 
 
1971-
1980 
0.90 
-0.97, 
2.77 
0.34 3.32 
-0.08, 
6.73 
0.06 0.20 
-2.31, 
2.70 
0.88 
 
1981-
1990 
-1.40 
-3.75, 
0.95 
0.24 -3.68 
-8.23, 
0.87 
0.11 -0.76 
-3.80, 
2.27 
0.62 
 
1991-
2000 
0.47 
-0.67, 
1.61 
0.42 0.47 
-2.13, 
3.07 
0.72 -0.40 
-1.64, 
0.85 
0.53 
 
2001-
2010 
-1.50 
-3.03, 
0.03 
0.05 -5.68 
-10.23, -
1.13 
0.02 -0.67 
-2.21, 
0.87 
0.40 
 
1. Regression spline models: response rate (%) = b0 + b1 x X1 + b2 x X2 + b3  x X3 + b4 x X4 
 X1= median year of data collection (continuous variable) 
 X2= X1-1981      if X1 ≥1981, 0 otherwise 
 X3= X1-1991      if X1 ≥1991, 0 otherwise 
 X4= X1-2001      if X1 ≥2001, 0 otherwise 
2. The β regression coefficient represents the yearly change in response rate (%) in each data 
collection period. 
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6 Discussion  
Overall, the quality of reporting of response rates and reasons for non-participation 
was very poor, especially for control series. Subject participation in case-control studies 
of cancer has declined over the past 30 years, and this decline was steeper in studies 
conducted after 2000. 
Quality of reporting of response rates 
As presented in manuscript 1, there was a rather poor reporting of relevant 
information on subject response rates in case-control studies of cancer, especially 
regarding reasons for non-participation. In addition, subject eligibility criteria were often 
unclear. Although the proportion of studies not reporting any information on response 
rates has declined slightly over time, overall reporting quality did not seem to have 
improved substantially. There was a tendency for better quality of reporting in case 
series, followed by population control series, and lastly by medical source control series. 
It seems that many authors did not have a clear understanding of the distinction 
between ―response rate‖, ―participation rate‖, and ―cooperation rate‖, as the terms were 
often used interchangeably. This problem is particularly apparent in studies for which full 
subject eligibility could not be ascertained at the initial stage, such as in studies using 
random digit dialing. While it is reasonable to exclude ineligible subjects from the 
denominator of response rate; it is, however, difficult to define correctly and consistently 
―eligibility‖ and the consequence of it can be detrimental. As Nattinger et al. (44) 
demonstrated, changing the definition of ―eligible subject‖ could modify their subject 
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response rate from 57% to 70%. In the context of case-control studies of cancer where the 
sampling frame usually differs between case and control series, poorly or incorrectly 
defined eligibility criteria for cases and controls could cause an unpredictable level of 
selection bias, despite a reported high response rate. 
Reviews carried out in the early 2000s reported that about half of the case-control 
studies provided no information regarding their response rates (16) (50) , whereas similar 
to our finding, a more recent review of survey research reported fewer studies without 
any information on response rates (51). Our estimates of the numbers of studies with very 
poor information ranged from about 12% among population control series to 45% among 
medical source control series.  However, these reviews are not directly comparable 
because they covered different diseases, different topics, different populations and 
different eras. Unlike the other reviews, we also reviewed and extracted information on 
study participation from previous methodological publications of our surveyed studies. In 
any case, even the most favorable of these estimates is not encouraging. There are too 
many published studies with almost no useful information on response rates.  
We observed that the quality of reporting seemed to peak in our 1995 sample. We 
also  observed that since then, fewer studies reported non-participation of cases due to 
medical source obstacles and fewer considered these non-respondents eligible. We 
conjecture that the quality of response rate reporting improved up to that point because of 
increasing awareness of the importance of response rate as a contributor to study quality, 
and it declined afterwards because of  a decrease in civic participation in general, 
increasing saturation with various types of solicitations and the increasing obstacles and 
―protections‖ imposed by ethics review authorities in accessing subjects, resulting in a 
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greater reluctance to reveal the true response rates to journal editors and reviewers, 
coupled with increasing pressure on word counts.  
Time trends and study design determinants of response rates 
 As presented in manuscript 2, our results indicate that response rates in case-
controls studies of cancer have declined over the past 30 years, and that this decline was 
steeper in studies conducted after 2000. There was a greater decline of response rate in 
control series than in cases series. Non-participation due to subject refusal has increased 
over time, especially in the population control series. 
Very few studies examined the level of subject response rates in epidemiologic 
case-control studies. Previous reviews have examined the time trends of response rates in 
surveyed case-control studies conducted up to the early 2000s (16, 32, 34). Two reviews 
(16, 32, 34) concluded that no significant changes in response rates were observed in 
studies conducted until the late 1990s, and one review (16) concluded that significant 
declines of response rates in both cases and controls were observed in case-control 
studies conducted from 1970-2003. Our findings indicated that response rate did not 
change significantly from the 1970s to the 1990s, but that this rate only started to 
deteriorate significantly from the 2000s and the 1990s, for cases and for population 
controls, respectively. We did not observe a significant decline of response rates in 
medical source controls in studies conducted after 2000. 
Given the importance of response rate in case-control studies, it is essential to 
understand its determinants. By its nature our study was only capable of elucidating the 
role of study design variables on subject participation. We observed the highest response 
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rates in studies that interviewed subjects in person; however, using multiple methods did 
not improve subject participation, nor did we observe a decline in interview response rate 
or in biologic sample collection rate in studies involving invasive data collection. The 
lack of association between biologic sample collection and subject participation may be 
explained by the fact that in our surveyed studies, subjects were not obligated to provide 
biologic samples in order to participate in the studies. We were not able to explore the 
influence of incentives on response rates since this information was provided in 2% of the 
surveyed studies. In addition to the aforementioned study design factors, we observed 
that additional factors, such as location of the study population and type of respondent 
accepted, also influenced the response rates in case-control studies of cancer.  
Strength and Limitations  
 To our knowledge, our review included the largest sample of questionnaire-based 
case-control studies of cancer published in the past three decades, which enabled us to 
explore in great detail the current and past practice of reporting of response rates. 
However, there are a few considerations that may affect the interpretation of our study. 
First, as there is no consensus in how response rate should be calculated and reported, 
some may think that our definition is too conservative or rigid. Second, we reviewed 
articles from 15 journals that in our view were likely to have published a large fraction of 
epidemiological case-control studies of cancer. There have been other journals, but from 
an initial review these would not have accounted for large numbers of articles of the 
types we were searching for. Furthermore, the journals we selected probably represent the 
―best case scenarios‖ of high quality epidemiology journals; the quality of reporting of 
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response rates and the level of subject participation in studies published in other journals 
may be even lower.   
 It is possible that some reported response rates were biased in our sampled 
studies; due to the decline in subject participation, studies, especially more recent ones, 
could tend to report and calculate their response rates in more favorable methods.  We 
attempted to minimize this problem by recalculating response rates based on standardized 
criteria, although this attempt may not have fully succeeded since we sometimes had to 
accept authors’ claims of their response rates because of the paucity of information. But 
as we argued, authors have not been consistent in their operational definitions and have a 
tendency to exaggerate their response rates by neglecting to include some categories of 
non-participants among eligible subjects. We observed in our surveyed studies that the 
response rates seemed to be higher in studies with low quality of reporting. This might 
indicate that despite our attempts to recalculate true response rates in these studies, there 
was crucial information hidden from view in some publications. In our view, there is little 
probability of selection bias in our study since we reviewed and selected every article that 
was published in the selected years and journals. There is little evidence to believe that 
response rates and its reporting in articles published from other years during the past 
three decades would differ meaningfully from those reported in our selected samples. We 
do not intend to generalize our findings to other case-control studies of cancer conducted 
and published in other periods nor do we intend to infer our findings to studies conducted 
on other study populations.   
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6 Conclusion 
 
Our study and previous literature on the topic of response rates in epidemiologic 
studies observed a decline in subject participation over the past decades and a generally 
poor quality of reporting for this methodological factor in published studies. Although 
low response rate itself does not infer low study validity, studies with low level of subject 
participation have a greater chance for selection biases when compared to studies with 
high level of participation. However, due to the inconstant methods of reporting for 
response rate in published studies, it is very difficult for readers to understand and to 
assess the validity of each study. Consequently, epidemiologists and public health 
practitioners should be cautious about this problem as biased results could influence 
scientific interpretations and decision making in public health. 
 
 
 
 
 
 
 
 
 
 
 104 
 
7 References 
 
1. Last JM, Association IE. A dictionary of epidemiology: Oxford Univ Press; 
2001. 
2. Breslow NE, Day NE. Statistical methods in cancer research: International 
Agency for Research on Cancer Lyon; 1987. 
3. Rothman KJ, Greenland S, Lash TL. Modern epidemiology: Lippincott 
Williams & Wilkins; 2008. 
4. Santos SI. Cancer epidemiology, principles and methods. Cancer 
epidemiology, principles and methods. 1999. 
5. Lane-Claypon JE. A Further Report on Cancer of the Breast with Special 
Reference to its Associated Antecedent Conditions. Ministry of Health Reports on 
Public Health and Medical Subjects. 1926(32). 
6. Cole P. The evolving case-control study. Journal of Chronic Diseases. 
1979;32(1):15-27. 
7. Paneth N, Susser E, Susser M. Origins and early development of the case-
control study: Part 2, The case-control study from Lane-Claypon to 1950. Sozial-und 
Präventivmedizin. 2002;47(6):359-65. 
8. Doll R, Hill AB. Study of the Aetiology of Carcinoma of the Lung. British 
medical journal. 1952;2(4797):1271. 
9. Levin ML, Goldstein H, Gerhardt PR. Cancer and tobacco smoking: a 
preliminary report. Journal of the American Medical Association. 1950;143(4):336-
8. 
10. Schrek R, Baker LA, Ballard GP, Dolgoff S. Tobacco smoking as an etiologic 
factor in disease. I. Cancer. Cancer research. 1950;10(1):49-58. 
11. Winder E, Graham E. Tobacco smoking as a possible etiologic factor in 
bronchogenic carcinoma. JAMA. 1950;143:329-36. 
12. Lewallen S, Courtright P. Epidemiology in practice: case-control studies. 
Community Eye Health. 1998;11(28):57. 
13. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of Controls 
in Case-Control Studies: II. Types of Controls. American journal of epidemiology. 
1992;135(9):1029-41. 
14. Galea S, Tracy M. Participation rates in epidemiologic studies. Annals of 
epidemiology. 2007;17(9):643-53. 
15. Morton S, Bandara DK, Robinson EM, Carr PEA. In the 21st Century, what is 
an acceptable response rate? Australian and New Zealand journal of public health. 
2012;36(2):106-8. 
16. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic 
studies: a survey of practice. American journal of epidemiology. 2006;163(3):197-
203. 
17. Olson SH, Voigt LF, Begg CB, Weiss NS. Reporting participation in case-
control studies. Epidemiology. 2002;13(2):123-6. 
18. Groves RM. Nonresponse rates and nonresponse bias in household surveys. 
Public Opinion Quarterly. 2006;70(5):646-75. 
 105 
 
19. Harris MA. Invited commentary: evaluating epidemiologic research 
methods—the importance of response rate calculation. American journal of 
epidemiology. 2010;172(6):645-7. 
20. Slattery ML, Edwards SL, Caan BJ, Kerber RA, Potter JD. Response rates 
among control subjects in case-control studies. Annals of epidemiology. 
1995;5(3):245-9. 
21. Research AAfPO. Standard Definitions: Final Dispositions of Case Codes and 
Outcome Rates for Surveys 2011 [cited 2014 December 11]. Available from: 
http://www.aapor.org/AAPORKentico/AAPOR_Main/media/MainSiteFiles/Standar
dDefinitions2011_1.pdf. 
22. Association TMRaI. Standards: response rate calculation formula  [cited 2015 
03-04]. Available from: http://mria-arim.ca/about-mria/standards/response-rate-
calculation-formula. 
23. Canada PWaGS. Standards and Guidelines for: Response Rate  [updated 
2014-11-19; cited 2015 03-04]. Available from: http://www.tpsgc-pwgsc.gc.ca/rop-
por/rapports-reports/comitephone-panelphone/page-06-eng.html. 
24. Jones J. The effects of non-response on statistical inference. Journal of health 
& social policy. 1996;8(1):49-62. 
25. Harris MA, Levy AR, Teschke KE. Personal privacy and public health: 
Potential impacts of privacy legislation on health research in Canada. Canadian 
Journal of Public Health/Revue Canadienne de Sante'e Publique. 2008:293-6. 
26. der Wiel A, Van Exel E, De Craen A, Gussekloo J, Lagaay A, Knook D, et al. A 
high response is not essential to prevent selection bias: results from the Leiden 85-
plus study. Journal of clinical epidemiology. 2002;55(11):1119-25. 
27. Groves RM. Survey errors and survey costs: John Wiley & Sons; 2004. 
28. Keeble C, Barber S, Law GR, Baxter PD. Participation Bias Assessment in 
Three High-Impact Journals. SAGE Open. 2013;3(4):2158244013511260. 
29. Moorman P, Newman B, Millikan R, Tse C-K, Sandler D. Participation rates in 
a case-control study:: The impact of age, race, and race of interviewer. Annals of 
epidemiology. 1999;9(3):188-95. 
30. Hartge P. Participation in population studies. Epidemiology. 2006;17(3):252-
4. 
31. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. 
The Strengthening the Reporting of Observational Studies in Epidemiology 
[STROBE] statement: guidelines for reporting observational studies. Gaceta 
Sanitaria. 2008;22(2):144-50. 
32. Olson SH. Reported participation in case-control studies: changes over time. 
American journal of epidemiology. 2001;154(6):574-81. 
33. Rogers A, Murtaugh M, Edwards S, Slattery M. Contacting controls: are we 
working harder for similar response rates, and does it make a difference? American 
journal of epidemiology. 2004;160(1):85-90. 
34. Stang A, Ahrens W, Jöckel K-H. Control response proportions in population-
based case-control studies in Germany. Epidemiology. 1999;10(2):181-3. 
35. Madigan MP, Troisi R, Potischman N, Brogan D, Gammon MD, Malone KE, et 
al. Characteristics of respondents and non-respondents from a case-control study of 
 106 
 
breast cancer in younger women. International Journal of Epidemiology. 
2000;29(5):793-8. 
36. Richiardi L, Boffetta P, Merletti F. Analysis of nonresponse bias in a 
population-based case–control study on lung cancer. Journal of clinical 
epidemiology. 2002;55(10):1033-40. 
37. Sykes LL, Walker RL, Ngwakongnwi E, Quan H. A systematic literature review 
on response rates across racial and ethnic populations. Canadian Journal of Public 
Health/Revue Canadienne de Sante'e Publique. 2010:213-9. 
38. Bunin GR, Spector LG, Olshan AF, Robison LL, Roesler M, Grufferman S, et al. 
Secular trends in response rates for controls selected by random digit dialing in 
childhood cancer studies: a report from the Children's Oncology Group. American 
journal of epidemiology. 2007;166(1):109-16. 
39. Castaño-Vinyals G, Nieuwenhuijsen MJ, Moreno V, Carrasco E, Guinó E, 
Kogevinas M, et al. Participation rates in the selection of population controls in a 
case-control study of colorectal cancer using two recruitment methods. Gaceta 
Sanitaria. 2011;25(5):353-6. 
40. Bernstein L. Control recruitment in population-based case-control studies. 
Epidemiology. 2006;17(3):255-7. 
41. Curtin R, Presser S, Singer E. Changes in telephone survey nonresponse over 
the past quarter century. Public opinion quarterly. 2005;69(1):87-98. 
42. Beskow LM, Sandler RS, Weinberger M. Research recruitment through US 
central cancer registries: balancing privacy and scientific issues. American journal of 
public health. 2006;96(11):1920-6. 
43. Deapen D. Cancer surveillance and information: balancing public health with 
privacy and confidentiality concerns (United States). Cancer Causes Control. 
2006;17(5):633-7. 
44. Nattinger AB, Pezzin LE, Sparapani RA, Neuner JM, King TK, Laud PW. 
Heightened attention to medical privacy: challenges for unbiased sample 
recruitment and a possible solution. American journal of epidemiology. 
2010:kwq220. 
45. Sugarman J, Regan K, Parker B, Bluman LG, Schildkraut J. Ethical 
ramifications of alternative means of recruiting research participants from cancer 
registries. Cancer. 1999;86(4):647-51. 
46. van Panhuis WG, Paul P, Emerson C, Grefenstette J, Wilder R, Herbst AJ, et al. 
A systematic review of barriers to data sharing in public health. BMC public health. 
2014;14(1):1144. 
47. Mengting Xu LR, Sally Campbell, Javier Pintos, Jack Siemiatycki. Patterns and 
Trends in Quality of Reporting of Response Rates in Case-Control Studies of Cancer 
University of Montreal; 2016. 
48. Morton LM. Encouraging participation in medical research: what strategies 
work? Journal of clinical epidemiology. 2008;61(10):969. 
49. Sneyd MJ, Cox B. Commentary: Decreasing response rates require 
investigators to quantify and report the impact of selection bias in case–control 
studies. International journal of epidemiology. 2011;40(5):1355-7. 
 107 
 
50. Pocock SJ, Collier TJ, Dandreo KJ, De Stavola BL, Goldman MB, Kalish LA, et al. 
Issues in the reporting of epidemiological studies: a survey of recent practice. BmJ. 
2004;329(7471):883. 
51. Bennett C, Khangura S, Brehaut JC, Graham ID, Moher D, Potter BK, et al. 
Reporting guidelines for survey research: an analysis of published guidance and 
reporting practices. PLoS medicine. 2011;8(8):1117. 
52. Stang A. Appropriate epidemiologic methods as a prerequisite for valid study 
results. European journal of epidemiology. 2008;23(12):761-5. 
53. Bastuji-Garin S, Sbidian E, Gaudy-Marqueste C, Ferrat E, Roujeau J-C, Richard 
M-A, et al. Impact of STROBE statement publication on quality of observational 
study reporting: interrupted time series versus before-after analysis. PloS one. 
2013;8(8):e64733. 
54. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in 
case-control studies. I. Principles. Am J Epidemiol. 1992;135(9):1019-28. 
55. Johnson T, Owens L, editors. Survey response rate reporting in the 
professional literature. 58th Annual Meeting of the American Association for Public 
Opinion Research, Nashville; 2003. 
56. Sandler DP. On revealing what we’d rather hide: the problem of describing 
study participation. Epidemiology. 2002;13(2):117. 
57. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et 
al. The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. International 
Journal of Surgery. 2014;12(12):1495-9. 
58. Santos SI. Cancer epidemiology, principles and methods. International 
Agency for Research on Cancer: Lyon. 1999. 
59. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of Controls 
in Case-Control Studies: I. Principles. American journal of epidemiology. 
1992;135(9):1019-28. 
 108 
 
8  Appendix 1  
Examples of the definitions of response rates, cooperation rates and participation rates 
from different sources. 
 
 
 
Terms used to 
address subject 
participation 
Definitions 
Response Rate   The percentage of people interviewed of those who were 
selected and eligible for the study (Slattery et al(20)).  
 The number of completed or returned survey instruments 
(questionnaires, interviews, etc.) divided by the total number of 
persons who would have been surveyed if all had participated   
( A dictionary of epidemiology(1)). 
 The number of complete interviews with reporting units 
divided by the number of eligible reporting units in the sample 
(AAPOR(21)). 
Cooperation Rate  The percentage of people interviewed of those who were 
contacted (Slattery et al(20)). 
 The proportion of all cases interviewed of all eligible units ever 
contacted (AAPOR(21)). 
Participation Rate  This term is used broadly, to refer to either ―response rates‖ or 
―cooperation rates‖ (Morton et al (16)). 
